WO2018087699A2 - Méthodes et compositions pour une modulation immunitaire adaptative - Google Patents

Méthodes et compositions pour une modulation immunitaire adaptative Download PDF

Info

Publication number
WO2018087699A2
WO2018087699A2 PCT/IB2017/057025 IB2017057025W WO2018087699A2 WO 2018087699 A2 WO2018087699 A2 WO 2018087699A2 IB 2017057025 W IB2017057025 W IB 2017057025W WO 2018087699 A2 WO2018087699 A2 WO 2018087699A2
Authority
WO
WIPO (PCT)
Prior art keywords
agonist
tlr9
agonists
tlr
ova
Prior art date
Application number
PCT/IB2017/057025
Other languages
English (en)
Other versions
WO2018087699A3 (fr
Inventor
Burton F. Dickey
Michael J. TUVIM
Scott E. EVANS
Magnus Hook
David P. HUSTON
Margarita MARTINEZ-MOCZYGEMBA
Brenton SCOTT
Original Assignee
The Board Of Regents Of The University Of Texas System
Pulmotect, Inc.
The Texas A&M University System
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to CN201780076197.9A priority Critical patent/CN110234401B/zh
Application filed by The Board Of Regents Of The University Of Texas System, Pulmotect, Inc., The Texas A&M University System filed Critical The Board Of Regents Of The University Of Texas System
Priority to BR112019009469A priority patent/BR112019009469A2/pt
Priority to CA3043480A priority patent/CA3043480A1/fr
Priority to KR1020197016471A priority patent/KR102515202B1/ko
Priority to JP2019525874A priority patent/JP7145853B2/ja
Priority to AU2017356673A priority patent/AU2017356673B2/en
Priority to US16/348,829 priority patent/US11826422B2/en
Priority to MX2019005502A priority patent/MX2019005502A/es
Priority to EP17870060.5A priority patent/EP3538218A4/fr
Publication of WO2018087699A2 publication Critical patent/WO2018087699A2/fr
Publication of WO2018087699A3 publication Critical patent/WO2018087699A3/fr
Priority to IL266562A priority patent/IL266562A/en
Priority to US18/484,667 priority patent/US20240033348A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/35—Allergens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/35—Allergens
    • A61K39/36—Allergens from pollen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/117—Nucleic acids having immunomodulatory properties, e.g. containing CpG-motifs
    • H—ELECTRICITY
    • H04—ELECTRIC COMMUNICATION TECHNIQUE
    • H04B—TRANSMISSION
    • H04B1/00—Details of transmission systems, not covered by a single one of groups H04B3/00 - H04B13/00; Details of transmission systems not characterised by the medium used for transmission
    • H04B1/02—Transmitters
    • H04B1/04—Circuits
    • H—ELECTRICITY
    • H04—ELECTRIC COMMUNICATION TECHNIQUE
    • H04B—TRANSMISSION
    • H04B1/00—Details of transmission systems, not covered by a single one of groups H04B3/00 - H04B13/00; Details of transmission systems not characterised by the medium used for transmission
    • H04B1/06—Receivers
    • H04B1/16—Circuits
    • H—ELECTRICITY
    • H04—ELECTRIC COMMUNICATION TECHNIQUE
    • H04B—TRANSMISSION
    • H04B1/00—Details of transmission systems, not covered by a single one of groups H04B3/00 - H04B13/00; Details of transmission systems not characterised by the medium used for transmission
    • H04B1/38—Transceivers, i.e. devices in which transmitter and receiver form a structural unit and in which at least one part is used for functions of transmitting and receiving
    • H04B1/40—Circuits
    • H—ELECTRICITY
    • H04—ELECTRIC COMMUNICATION TECHNIQUE
    • H04B—TRANSMISSION
    • H04B1/00—Details of transmission systems, not covered by a single one of groups H04B3/00 - H04B13/00; Details of transmission systems not characterised by the medium used for transmission
    • H04B1/69—Spread spectrum techniques
    • H04B1/713—Spread spectrum techniques using frequency hopping
    • H—ELECTRICITY
    • H04—ELECTRIC COMMUNICATION TECHNIQUE
    • H04B—TRANSMISSION
    • H04B1/00—Details of transmission systems, not covered by a single one of groups H04B3/00 - H04B13/00; Details of transmission systems not characterised by the medium used for transmission
    • H04B1/69—Spread spectrum techniques
    • H04B1/713—Spread spectrum techniques using frequency hopping
    • H04B1/715—Interference-related aspects
    • H—ELECTRICITY
    • H04—ELECTRIC COMMUNICATION TECHNIQUE
    • H04B—TRANSMISSION
    • H04B1/00—Details of transmission systems, not covered by a single one of groups H04B3/00 - H04B13/00; Details of transmission systems not characterised by the medium used for transmission
    • H04B1/69—Spread spectrum techniques
    • H04B1/713—Spread spectrum techniques using frequency hopping
    • H04B1/7156—Arrangements for sequence synchronisation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/544—Mucosal route to the airways
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates

Definitions

  • Asthma is a complex inflammatory disease of the lungs characterized by eosinophilic inflammation, elevated serum IgE levels, mucus production, and reversible airflow obstruction.
  • the currently available therapeutics for treating allergic asthma provide immediate symptomatic relief and some even reduce airway inflammation; however, they remain inadequate. Thus, additional strategies for treating allergic diseases are needed.
  • IgE plays an essential role in type I hypersensitivity, which manifests various allergic diseases, such as allergic asthma, allergic rhinitis, food allergy, and some types of chronic urticaria and atopic dermatitis. IgE also plays a pivotal role in allergic conditions, such as anaphylactic reactions to certain drugs, bee stings, and antigen preparations used in specific desensitization immunotherapy.
  • Embodiments are directed to methods and compositions for modulating an immune response, as well as composition and methods for mitigating lower respiratory infections in patients with underlying inflammatory disease (e.g., COPD).
  • underlying inflammatory disease e.g., COPD
  • the immune response is an allergic immune response.
  • the immune response is a type I hypersensitivity response.
  • the immune response is an IgE mediated immune response.
  • the subject has allergic asthma or allergic rhinitis.
  • TLR agonists in particular a combination of TLR2/6 and TLR9 agonist (e.g., TLR9 oligonucleotide agonist (O) / PAM2CSK4 (S-[2,3- bis(palmitoyloxy)-(2RS)-propyl]-[R]-cysteinyl-[S]-seryl-[S]-lysyl-[S]-lysyl-[S]-lysyl-[S]-lysyl- [S]-lysyl- [S]-lysyl- [S]-lysyl- [S]-lysine x 3 CF3COOH) (P) along with an antigen (e.g., ovalbumin (OVA)) suppresse
  • hypersensitivity refers to an undesirable immune system response. Hypersensitivity is divided into four categories. Type I hypersensitivity includes allergies (e.g., Atopy, Anaphylaxis, or Asthma).
  • Type II hypersensitivity is cytotoxic/antibody mediated (e.g., Autoimmune hemolytic anemia, Thrombocytopenia, Erythroblastosis fetalis, or Goodpasture's syndrome).
  • Type III is immune complex diseases (e.g., Serum sickness, Arthus reaction, or SLE).
  • Type IV is delayed-type hypersensitivity (DTH), Cell-mediated immune memory response, and antibody-independent (e.g., Contact dermatitis, Tuberculin skin test, or Chronic transplant rejection).
  • DTH delayed-type hypersensitivity
  • the subject has been diagnosed with the disease or condition or has been previously treated for the disease or condition. It is specifically contemplated that the subject is a human subject in certain embodiments. In other embodiments, the subject is a mammal that can develop or have the indicated disease or condition or experience the physiologic effects described herein.
  • allergy means a disorder characterized by excessive activation of mast cells and basophils by IgE.
  • the excessive activation of mast cells and basophils by IgE results (either partially or fully) in an inflammatory response.
  • the inflammatory response is local.
  • the inflammatory response results in the narrowing of airways (i.e., bronchoconstriction).
  • the inflammatory response results in inflammation of the nose (i.e., rhinitis).
  • the inflammatory response is systemic (i.e., anaphylaxis).
  • Additional aspects are directed to methods for attenuating a type 2 allergic response or antigen specific IgE levels in a subject, comprising administering an effective amount of at least two TLR agonists to a subject susceptible to type I hypersensitivity, e.g., allergies and/or allergen induced asthma.
  • a subject susceptible to type I hypersensitivity e.g., allergies and/or allergen induced asthma.
  • the subject has been exposed to an allergen. It is contemplated that the response or antigen- specific IgE levels is reduced in some embodiments.
  • the composition is administered prophylactically.
  • the composition is administered prophylactically to an asthmatic or type I hypersensitive subject.
  • the TLR agonists are selected from the group consisting of TLR2/1, TLR2/6, TLR3, TLR4, TLR5, TLR9, and TLR7 agonist.
  • the TLR agonist composition comprises a TLR9 agonist and a TLR2/6 agonist.
  • the TLR2/6 agonist can be a diacylated lipopolypeptide, such as PAM2CSK4.
  • the TLR9 agonists can be an TLR9 oligonucleotide agonist, including but not limited to type A CpG oligodeoxynucleotide, a type B CpG oligodeoxynucleotide, a type C CpG oligodeoxynucleotides or other oligodeoxynucleotides.
  • the TLR9 oligonucleotide agonist is a type C oligodeoxynucleotide (ODN), such as ODN2395 (5'-tcgtcgttttcggcgcgcgccg-3' (22 mer) (SEQ ID NO: l)) or OD M362 (5'-tcgtcgtcgttcgaacgacgttgat-3 ' (25 mer) (SEQ ID NO:2)) or ODN10101 (5'-tcgtcgttttcgcgcgcgcgcgcg-3 ' (SEQ ID NO:3)) or 9 mer (5'- cgcgaagcg-3 ' (SEQ ID NO:4)) or H-Tel 22 (5'-agggttagggttagggttaggg-3 ' (SEQ ID NO: 5)) or analog thereof.
  • ODN2395 5'-tcgtcgt
  • the TLR9 oligonucleotide has a phosphorothioate or phosphodiester backbone.
  • Certain formulations or methods can include administration of 1, 2, 3, 4, or more TLR9 oligonucleotide agonist individually or in combination.
  • the TLR agonist composition can include an anti-inflammatory agent and/or other pharmaceutically acceptable excipient.
  • the antiinflammatory agent is selected from betamethasone, triamcinolone, dexamethasone, prednisone, mometasone, flunisolide and budesonide, particularly budesonide.
  • the pharmaceutical excipient is glycerol.
  • the TLR agonist composition comprises PAM2CSK4 and an TLR9 oligonucleotide agonist.
  • TLR 9 In certain aspects molar ratio of TLR2/6 agonist (e.g., PAM2CSK) to TLR9 agonist (e.g., ODN) is or is about 1 : 1, 2: 1, 3 : 1, 4: 1, 5 : 1, 6: 1, 7: 1, 8: 1, 1 :2, 1 :3, 1 :4, 1 : 5, 1 :6, 1 :7, or 1 :8.
  • the TLR agonist composition is administered in combination with an allergen.
  • the allergen is administered or a subject is exposed to the allergen before; during; after; before and during; before and after; during and after; or before, during and after administration of the TLR agonist composition.
  • the compositions can be administered 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or more times (or any range derivable therein).
  • the compositions are administered every 4, 6, 8, 10, 12, or 24 hours, or every 1, 2, 3, 4, 5, 6, 7 days, weeks, or months, and any range derivable therein.
  • the compositions are administered continually on a daily or weekly basis.
  • Certain embodiments are directed to suppressing type 2 (or Th2 mediated) allergic inflammation or type I hypersensitivity by administering a combination of TLR agonist.
  • a target antigen or allergen is administered in combination with TLR agonist composition.
  • the subject has been diagnosed with or identified as having chronic asthma.
  • the subject has been diagnosed with and/or evaluated for type-2 allergies prior to being given the TLR agonists.
  • the patient is already being treated for allergy or asthma.
  • the patient is also administered asthma medication, such as a corticosteroid, epinephrine, or short-term beta2-agonist.
  • the patient is taking an antihistamine or other allergy treatment.
  • the patient is taking an immune-suppressant.
  • Type I hypersensitivity (or immediate hypersensitivity) is an allergic reaction provoked by reexposure to a specific type of antigen referred to as an allergen.
  • Type I is not to be confused with Type II, Type III, or Type IV hypersensitivities. Exposure may be by ingestion, inhalation, injection, or direct contact.
  • type 1 hypersensitivity an antigen is presented to CD4+ Th2 cells specific to the antigen that stimulates B-cell production of IgE antibodies also specific to the antigen.
  • the difference between a normal infectious immune response and a type 1 hypersensitivity response is that in type 1 hypersensitivity the antibody is IgE instead of IgA, IgG, or IgM.
  • the IgE antibodies bind to Fes receptors on the surface of tissue mast cells and blood basophils.
  • the term "antigen" is a molecule capable of being bound by an antibody or T-cell receptor.
  • An antigen is additionally capable of inducing a humoral immune response and/or cellular immune response leading to the production of B- and/or T- lymphocytes.
  • the structural aspect of an antigen e.g., three-dimensional conformation or modification (e.g., phosphorylation), giving rise to a biological response is referred to herein as an "antigenic determinant" or "epitope.”
  • B- lymphocytes respond to foreign antigenic determinants via antibody production, whereas T-lymphocytes are the mediator of cellular immunity.
  • antigenic determinants or epitopes are those parts of an antigen that are recognized by antibodies, or in the context of an MHC, by T-cell receptors.
  • An antigenic determinant need not be a contiguous sequence or segment of protein and may include various sequences that are not immediately adjacent to one another.
  • binding moieties other than antibodies and be engineered to specifically bind to an antigen e.g., aptamers, avimers, and the like.
  • allergen is a substance(s) containing antigens that can cause an undesired (e.g., a Type 1 hypersensitive) immune response (i.e., an allergic response or reaction) in a subject.
  • a Type 1 hypersensitive immune response i.e., an allergic response or reaction
  • Allergens include, but are not limited to, plant allergens (e.g., pollen, ragweed allergen), insect allergens, insect sting allergens (e.g., bee sting allergens), animal allergens (e.g., pet allergens, such as animal dander or cat Fel d 1 antigen), latex allergens, mold allergens, fungal allergens, cosmetic allergens, drug allergens, food allergens, dust, insect venom, viruses, bacteria, etc.
  • plant allergens e.g., pollen, ragweed allergen
  • insect allergens e.g., insect sting allergens
  • animal allergens e.g., pet allergens, such as animal dander or cat Fel d 1 antigen
  • latex allergens e.g., mold allergens, fungal allergens, cosmetic allergens, drug allergens, food allergens, dust, insect venom, viruses, bacteria, etc.
  • Food allergens include, but are not limited to milk allergens, egg allergens, nut allergens (e.g., peanut or tree nut allergens, etc.), fish allergens, shellfish allergens, soy allergens, legume allergens, seed allergens and wheat allergens.
  • Insect sting allergens include allergens that are or are associated with bee stings, wasp stings, hornet stings, yellow jacket stings, etc.
  • Insect allergens also include house dust mite allergens (e.g., Der PI antigen) and cockroach allergens.
  • Drug allergens include allergens that are or are associated with antibiotics, NSAIDs, anesthetics, etc.
  • Pollen allergens include grass allergens, tree allergens, weed allergens, flower allergens, etc.
  • Subjects that develop or are at risk of developing an undesired immune response to any of the allergens provided herein may be treated with any of the compositions and methods provided herein.
  • Subjects that may be treated with any of the compositions and methods provided also include those who have or are at risk of having an allergy to any of the allergens provided.
  • “Allergens associated with an allergy” are allergens that generate an undesired immune response that results in, or would be expected by a clinician to result in, alone or in combination with other allergens, an allergic response or reaction or a symptom of an allergic response or reaction in a subject.
  • Type(s) of allergens means molecules that share the same, or substantially the same, antigenic characteristics in the context of an undesired immune response.
  • the allergens may be proteins, polypeptides, peptides, or lipoproteins.
  • Certain embodiments are directed to compositions and methods for treating (including prophylactic treatment) or ameliorating a respiratory infection, in particular a lower respiratory infection.
  • the subject being treated has an underlying inflammatory disease.
  • Certain aspects are directed to a formulation or a method of administering an effective amount of a TLR9 agonist and a TLR2/6 agonist to an individual that has or is at risk of developing or acquiring a microbial infection.
  • the TLR2/6 agonist is a diacylated lipopeptide, such as PAM2CSK4.
  • the TLR9 agonist is an TLR9 oligonucleotide agonist.
  • the TLR9 agonists can be an TLR9 oligonucleotide agonist, including but not limited to type A CpG oligodeoxynucleotide, a type B CpG oligodeoxynucleotide, a type C CpG oligodeoxynucleotides or other oligodeoxynucleotides.
  • the TLR9 oligonucleotide agonist is ODN2395 (5'-tcgtcgttttcggcgcgcgccg-3 ' (22 mer) (SEQ ID NO: l)) or ODNM362 (5'-tcgtcgtcgttcgaacgacgttgat-3 ' (25 mer) (SEQ ID NO:2)) or ODN10101 (5'-tcgtcgttttcgcgcgcgcgcgcg-3 ' (SEQ ID NO:3)) or 9 mer (5'-cgcgaagcg-3 ' (SEQ ID NO:4)) or H-Tel 22 (5'-agggttagggttagggttaggg-3' (SEQ ID NO:5)) or analog thereof.
  • the TLR9 oligonucleotide has a phosphorothioate or phosphodiester backbone.
  • Certain formulations or methods can include administration of 1, 2, 3, 4, or more TLR9 oligonucleotide agonist individually or in combination.
  • the TLR9 agonist and the TLR2/6 agonist are administered in a nebulized formulation.
  • the TLR9 agonist and/or the TLR2/6 agonist can be administered in an amount from about 0.1, 1, 5, 10, 50 ⁇ g or mg/kg to about 5, 10, 50, 100 ⁇ g or mg/kg of the individual's body weight, including all values and ranges there between.
  • Certain embodiments are directed to a pharmaceutically acceptable composition
  • a pharmaceutically acceptable composition comprising a TLR9 agonist and a TLR2/6 agonist, an anti-inflammatory agent, and one or more pharmaceutical excipients, wherein said composition is sterile and essentially free of pathogenic microbes.
  • the TLR2/6 agonist is a diacylated lipopeptide, such as PAM2CSK4.
  • the TLR9 agonist is a TLR9 oligonucleotide agonist.
  • An anti-inflammatory agent can be selected from betamethasone, triamcinolone, dexamethasone, prednisone, mometasone, flunisolide and budesonide, particularly budesonide.
  • the pharmaceutical excipient is glycerol.
  • isolated can refer to a nucleic acid or polypeptide that is substantially free of cellular material, bacterial material, viral material, or culture medium (when produced by recombinant DNA techniques) of their source of origin, or chemical precursors or other chemicals (when chemically synthesized).
  • an isolated compound refers to one that can be administered to a subject as an isolated compound; in other words, the compound may not simply be considered “isolated” if it is adhered to a column or embedded in an agarose gel.
  • an "isolated nucleic acid fragment” or “isolated peptide” is a nucleic acid or protein fragment that is not naturally occurring as a fragment and/or is not typically in the functional state.
  • Moieties of the invention such as polypeptides, peptides, antigens, allergens, or immunogens, may be conjugated or linked covalently or noncovalently to other moieties such as adjuvants, proteins, peptides, supports, fluorescence moieties, or labels.
  • conjugated or linked covalently or noncovalently to other moieties such as adjuvants, proteins, peptides, supports, fluorescence moieties, or labels.
  • conjugated or “immunoconjugate” is broadly used to define the operative association of one moiety with another agent and is not intended to refer solely to any type of operative association, and is particularly not limited to chemical "conjugation.”
  • the term "providing” is used according to its ordinary meaning "to supply or furnish for use.”
  • the protein is provided directly by administering the protein, while in other embodiments, the protein is effectively provided by administering a nucleic acid that encodes the protein.
  • the invention contemplates compositions comprising various combinations of nucleic acid, antigens, peptides, and/or epitopes.
  • An allergen or antigen may be administered to the subject concurrently with one or more TLR agonists. In some embodiments, it is in the same composition as 1, 2, 3, or more TLR agonists. Moreover, it may be attached to one or more TLR agonists.
  • FIG. 1 Aerosolized OVA-O/P dampens the allergic immune response.
  • mice were harvested on day 21 for serologic and BAL analyses.
  • FIG. 2 Aerosolized O/P combined with OVA increases IgG2a, the Thl marker and the anti-inflammatory IgGl biomarker.
  • Sandwich ELISAs were used to measure total IgG, total IgGl, and total IgG2a levels from mouse serum samples as described in Materials and Methods. Comparison of mice treated with OVA alone (top panel, Group 6) with mice treated with OVA-O/P (top panel) did not reveal a significant difference in total IgG between the two groups.
  • FIG. 3 Allergic sensitization optimization with OVA as measured by inflammatory cells in BAL.
  • BAL from mice in 3A were analyzed for total and differential cell counts by Wright- Giemsa staining. Note how eosinophils (EOS) in Group 8 are elevated compared to all other groups.
  • EOS eosinophils
  • FIG. 4 Optimization of allergic sensitization measured by serum immunoglobulins.
  • FIG. 5 Inflammatory cell and mucin analysis for determination of most efficacious window with aerosolized OVA-O/P.
  • A) BALB/c mice (n 10) were immunized and aerosol challenged with either OVA alone (Group 2), or with OVA- O/P at various intervals as illustrated in A.
  • B) BAL was collected from six groups of mice (n 5) and total and differential cell counts were determined as described in Materials and Methods. Mice in Group 3 appear to have the least amount of EOS (orange bar) in the BAL as compared to other four groups.
  • FIG. 6 Determination of most efficacious window with aerosolized OVA- O/P by immunoglobulin analysis.
  • Comparison of total IgE in OVA treated mice (top panel, Group 2, 24.66 ⁇ 8.23) with OVA-O/P (Group 3 11.15 ⁇ 2.61) revealed a slight decrease in IgE levels.
  • comparison of OVA-IgE in OVA treated mice (second panel, Group 2, 3.77 ⁇ 1.00) with OVA-O/P (Group 3, 2.14 ⁇ 0.34) revealed a decrease in OVA-IgE levels.
  • Allergic asthma is a chronic respiratory disease associated with eosinophilic infiltration, increased mucus production, airway hyperresponsiveness (AHR), and airway remodeling (Barnes, Nature Reviews Immunology (2008), 8, 183-92).
  • AHR airway hyperresponsiveness
  • asthma Despite recent advances in understanding the pathophysiology of asthma, some therapies still rely on general immune suppression by corticosteroids, which can have undesirable side effects, while short-acting drugs can provide immediate symptomatic relief but are still somewhat inadequate (Fanta, N Engl J Med (2009), 360: 1002-14). Additional therapies are needed for treating allergic diseases.
  • the innate immune system provides immediate defense against invading pathogens (West et al., Annu. Rev. Cell Dev.Biol. (2006), 22:409-37; Ferrandon et al., Nat Rev Immunol (2007),7:862-74).
  • TLR Toll-like receptor
  • mice exposed mice to an aerosolized lysate of the bacterium non-typeable (unencapsulated) Haemophilus influenzae (NTHi), reasoning this would stimulate the epithelium with a mixture of pathogen-associated molecular patterns (PAMPs) in proportions reflecting a natural exposure (Clement et al., Am J Respir Crit Care Med (2008), 177: 1322-30).
  • PAMPs pathogen-associated molecular patterns
  • This exposure triggered a high level of resistance to a broad array of microbial pathogens, and provided host protection as evidenced by increased microbial killing within the lungs (Clement et al., Am J Respir Crit Care Med (2008), 177: 1322-30).
  • mice deficient in innate immune signaling components such as MyD88-/- and Trif-/- were examined (Duggan et al., Immunol (2011), 186(10):5916- 26; Evans et al., Br J Pharmacol (2011), 163 : 195-206).
  • innate immune signaling components such as MyD88-/- and Trif-/-
  • mice deficient in innate immune signaling components such as MyD88-/- and Trif-/- were examined (Duggan et al., Immunol (2011), 186(10):5916- 26; Evans et al., Br J Pharmacol (2011), 163 : 195-206).
  • the Trif-/- mice resistance by a bacterial lysate could not be induced in MyD88-/- mice, indicating that a subset of TLRs were involved in mediating this response.
  • TLR9 + TLR2/6 agonist improve survival more than 40%.
  • treatment with a CpG oligodeoxynucleotide (“ODN”, a TLR9 ligand) and Pam2CSK4 (“Pam2", a TLR2/6 ligand) resulted in a strong synergistic effect (Duggan et al., Immunol (2011), 186(10):5916-26).
  • mice pretreated with ODN/Pam2 survived challenges with P. aeruginosa, S. pneumoniae, or K. pneumoniae, in each case associated with a reduction in lung pathogen burden (Evans et al., Br J Pharmacol (2011), 163 : 195-206). These studies of the mechanism of inducible resistance have been complemented by studies of toxicity, biomarkers and dose-optimization (Evans et al., Br J Pharmacol (2011), 163 : 195-206).
  • the immune system is often divided into: (a) an innate immunity comprised of components that provide an immediate "first-line” of defense to continuously ward off pathogens and (b) an adaptive (acquired) immunity comprising the manufacture of antibodies and production or stimulation of T-cells specifically designed to target particular pathogens.
  • an adaptive immunity comprising the manufacture of antibodies and production or stimulation of T-cells specifically designed to target particular pathogens.
  • adaptive immunity the body can develop over time a specific immunity to particular pathogen(s). This response takes days to develop, and so is not effective at preventing an initial invasion, but it will normally prevent any subsequent infection, and also aids in clearing up longer-lasting infections.
  • Thl and Th2 Two types of effector CD4+ T helper cell responses can be induced by antigen presenting cells (APC), designated Thl and Th2, each designed to eliminate different types of pathogens.
  • APC antigen presenting cells
  • Thl response is characterized by the production of Interferon-gamma, which activates the bactericidal activities of macrophages, and induces B cells to make opsonizing (coating) and complement-fixing antibodies, and leads to "cell-mediated immunity".
  • Th2 response is characterized by the release of Interleukin 4, which results in the activation of B cells to make neutralizing non-cytolytic antibodies, leading to "humoral immunity” .
  • Thl responses are more effective against intracellular pathogens (viruses and bacteria that are inside host cells), while Th2 responses are more effective against extracellular bacteria, parasites including helminths and toxins.
  • cytotoxic T cells most of the CD4+ helper cells will die upon resolution of infection, with a few remaining as CD4+ memory cells.
  • IgE, the IgE synthesis pathway, and the IgE-mediated allergic/inflammatory pathway are all important targets in intervening with the pathological processes of allergy and asthma.
  • the B lymphocyte differentiation and maturation pathway that eventually generate IgE-secreting plasma cells go through the intermediate steps of IgE- expressing B lymphoblasts and involves the interaction with IgE-expressing memory B cells.
  • immunomodulating compositions include an allergen component or are administered in conjunction with an allergen component.
  • An allergen component can include one or more of the following allergens or a derivative thereof that include, but are not limited to: microbes (e.g., bacteria, virus, fungi), pollens (e.g., farm plant, tree, weed, grass), animal danders, hymenoptera venoms, insects (e.g., house dust mites), plant foods, and animal foods.
  • the allergen can be selected from one or more types of mites, e.g., Mite, House Dust (Dermatophagoid.es farinae); Mite, House Dust (Dermatophagoides pteronyssinus); Mite, Food/Storage (Acarus siro); Mite, House Dust (Blomia tropicalis); Mite, Storage (Chortoglyphus arcuates); Mite, House Dust (Euroglyphus maynei); Mite, Food/Storage (Lepidoglyphus destructor); Mite, Food/Storage (Tyrophagus putrescentiae); and Mite, House Dust (Glycyphagus domesticus).
  • the allergen can be selected from one or more types of venoms, e.g., Bumble Bee Venom (Bombus spp.); European Hornet Venom (Vespa crabro); Honey Bee (Apis mellifera); Mixed Hornet Venom (Dolichovespula spp); Mixed Paper Wasp Venom (Polistes spp.); Mixed Yellow Jacket Venom (Vespula spp.); White (bald)-faced Hornet Venom (Dolichovespula maculate); and Yellow Hornet Venom (Dolichovespula arenaria).
  • Bumble Bee Venom Bombus spp.
  • European Hornet Venom Vespa crabro
  • Honey Bee Apis mellifera
  • Mixed Hornet Venom Dolichovespula spp
  • Mixed Paper Wasp Venom Polyistes spp.
  • Mixed Yellow Jacket Venom Vespula spp.
  • White (bald)-faced Hornet Venom Dolichovespula mac
  • the allergen can be selected from one or more types of insects, e.g., Ant, Carpenter (Camponotus pennsylvanicus); Ant, Fire (Solenopsis invicta); Ant, Fire (Solenopsis richteri); Cockroach, American (Periplaneta Americana); Cockroach, German (Blattella germanica); Cockroach, Oriental (Blatta orientalis); Horse Fly (Tabanus spp.); House Fly (Musca domestica); Mayfly (Ephemeroptera spp.); Mosquito (Culicidae sp.); and Moth (Heterocera spp.).
  • insects e.g., Ant, Carpenter (Camponotus pennsylvanicus); Ant, Fire (Solenopsis invicta); Ant, Fire (Solenopsis richteri); Cockroach, American (Periplaneta Americana); Cockroach, German (Blattella germanica); Cock
  • the allergen can be selected from one or more types of epithelia, dander, and hair and feathers, e.g., Canary Feathers (Serinus canaria); Cat Epithelia (Felis domesticus)); Cattle Epithelia (Bos Taurus); Chicken Feathers (Gallus gallas (domesticus)); Dog Epithelia, Mixed Breeds (Canis familiaris); Duck Feathers (Anal platyrhynchos); Gerbil Epithelia (Meriones unguiculatus); Goat Epithelia (Capra hircus); goose Feathers (Anser domesticus); Guinea Pig (Cavia porcellus); Epithelia ((cobaya)); Hamster Epithelia (Mesocricetus auratus); Hog Epithelia (Sus scrofa); Horse Epithelia (Equus caballus); Mouse Epithelia (Mus musculus); Parakeet Feathers (Psittacid
  • the allergen can be selected from one or more types of dander, e.g., Cat dander/Antigen (Felis catus (domesticus)); Dog Dander, Mixed-Breed (Canis familiaris); and Poodle Dander (Canis familiaris).
  • dander e.g., Cat dander/Antigen (Felis catus (domesticus)); Dog Dander, Mixed-Breed (Canis familiaris); and Poodle Dander (Canis familiaris).
  • the allergen can be selected from one or more types of fungi, e.g., Acremonium strictum; Alternaria alternate; Aspergillus amstelodami; Aspergillus flavus; Aspergillus furmigatus; Aspergillus nidulans; Aspergillus niger; Aspergillus terreus; Aspergillus versicolor; Aureohasidium Pullulans; Bipolaris sorokiniana; Botrytis cinerea; Candida albicans; Chaetomium globosum; Cladosporium herbarum; Cladosporium sphaerospermum; Drechslere spicifera; Epicoccum nigrum; Epidermophyton floccosum; Fusarium moniliforme; Fusarium solani; Geotrichum candidum; Gliocladium viride; Helminthosporium solani; Microsporum canis; Cephalosporium acre
  • the allergen can be selected from one or more types of smuts, e.g., Barley Smut (Ustilago nuda); Bermuda Grass (ustilago); Smut (cynodontis); Corn Smut (Ustilago maydis); Johnson Grass (Sporisorium); Smut (cruentum); Oat Smut (Ustilago avenae); and Wheat Smut (Ustilago tritici).
  • smuts e.g., Barley Smut (Ustilago nuda); Bermuda Grass (ustilago); Smut (cynodontis); Corn Smut (Ustilago maydis); Johnson Grass (Sporisorium); Smut (cruentum); Oat Smut (Ustilago avenae); and Wheat Smut (Ustilago tritici).
  • the allergen can be selected from one or more types of grass pollens, e.g., Bahia (Paspalum notalum); Bermuda (Cynodon dactylon) Blue, Canada (Poa compressa); Brame, Smooth (Bromus inermis); Canary (Phalaris arundinacea); Corn (Zea mays); Couch/Quack (Elytrigia repens (Agropyron repens)); Johnson (Sorghum halepense); Kentucky Blue (Poa pratensis); Meadow Fescue (Festuca pratensis (elatior)); Oat, Cultivated (Avena sativa); Orchard (Dactylis glomerata); Red Top (Agrostis gigantean (alba)); Rye, Cultivated (Secale cereale); Rye, Giant Wild (Leymus (Elymus) condensatus); Rye, Italian (Lolium perenne s
  • the allergen can be selected from one or more types of weed pollens, e.g., Allscale (Atriplex polycarpa); Baccharis (Baccharis halimifolia); Baccharis (Baccharis sarothroides); Burrobrush (Hymenoclea salsola); Careless Weed (Amaranthus hybridus); Cocklebur (Xanthium strumarium (commune)); Dock, Yellow (Rumex crispus); Dog Fennel (Eupatorium capillifolium); Goldenrod (Solidago spp.); Hemp, Western Water (Amaranthus tuberculatus (Acnida tamariscina)); Iodine Bush (Allenrolfea occidentalis); Jerusalem Oak (Chenopodium botrys); Kochia/Firebush (Kochia scoparia); Lambs Quarter (Chenopodium album); Marsh Elder, Burweed (Iva xanthifolia); Marsh Elder, Narrowleaf
  • the allergen can be selected from one or more types of tree pollens, e.g., Acacia (Acacia spp.); Alder, European (Alnus glutinosa); Alder, Red (Alnus rubra); Alder, Tag (Alnus incana ssp.
  • tree pollens e.g., Acacia (Acacia spp.); Alder, European (Alnus glutinosa); Alder, Red (Alnus rubra); Alder, Tag (Alnus incana ssp.
  • Trichocarpa Cottonwood, Eastern (Populus deltoids); Cottonwood, Fremont (Populus fremontii); Cottonwood, Rio Grande (Populus wislizeni); Cottonwood, Western (Populus monilifera (sargentii)); Cypress, Arizona (Cupressus arizonica); Cypress, Bald (Taxodium distichum); Cypress, Italian (Cupressus sempervirens); Elm, American (Ulmus Americana); Elm, Cedar (Ulmus crassifolia); Elm, Siberian (Ulmus pumila); Eucalyptus (Eucalyptus globulus); Ralphberry (Celtis occidentalis); Hazelnut (Corylus Americana); Hazelnut, European (Corylus avellana); Hickory, Pignut (Carya glabra); Hickory, Shagbark (Carya ovata); Hickory, Shellbark (Carya laciniosa); H
  • the allergen can be selected from one or more types of wild and cultivated flowers, e.g., Daisy, Ox-Eye (Chrysanthemum leucanthemum); Dandelion (Taraxacum officinale); and Sunflower (Helianthus annuus).
  • the allergen can be selected from one or more types of cultivated farm plant pollens, e.g., Alfalfa (Medicago sativa); Castor Bean (Ricinus communis); Clover, Red (Trifolium pratense); Mustard (Brassica spp.); and Sugar Beet (Beta vulgaris).
  • Alfalfa Medicago sativa
  • Castor Bean Ricinus communis
  • Clover Red (Trifolium pratense); Mustard (Brassica spp.); and Sugar Beet (Beta vulgaris).
  • the allergen can be selected from one or more types of plant food, e.g., Almond (Prunus dulcis); Apple (Malus pumila); Apricot (Prunus armeniaca); Banana (Musa paradisiaca (sapientum)); Barley (Hordeum vulgare); Bean, Lima (Phaseolus lunates); Bean, Navy (Phaseolus vulgaris); Bean, Pinto (Phaseolus sp.) Bean, Red Kidney (Phaseolus sp.); Bean, String/Green (Phaseolus vulgaris); Blackberry (Rubus allegheniensis); Blueberry (Vaccinium sp.); Broccoli (Brassica oleracea var.
  • plant food e.g., Almond (Prunus dulcis); Apple (Malus pumila); Apricot (Prunus armeniaca); Banana (Musa paradisiaca (sapientum)); Barley (Hordeum vulgare); Bean,
  • the allergen can be selected from one or more types of fish and shellfish, e.g., Bass, Black (Micropterus sp.); Catfish (Ictalurus punctatus); Clam (Mercenaria mercenaria); Codfish (Gadus morhua); Crab (Callinectes sapidus); Flounder (Platichthys sp.); Halibut (Hippoglossus sp.); Lobster (Homarus americanus); Mackerel (Scomber scombrus); Oyster (Crassostrea virginica); Perch (Sebastes marinus); Salmon (Salmo solar); Sardine (Clupeiformes); Scallop (Pectan magellanicus); Shrimp (Penaeus sp.); Trout, Lake (Salvelinus sp.); and Tuna Fish (Thunnus sp.).
  • the allergen can be selected from one or more types of animal foods, e.g., Beef (Bus Taurus); Lamb (Ovis aries); and Pork (Sus scrofa).
  • the allergen can be selected from one or more types of poultry products, e.g., Chicken (Gallus gallus); Egg, Chicken, White (Gallus gallus); Egg, Chicken, Yolk (Gallus gallus); and Turkey (Meleagris gallopavo).
  • poultry products e.g., Chicken (Gallus gallus); Egg, Chicken, White (Gallus gallus); Egg, Chicken, Yolk (Gallus gallus); and Turkey (Meleagris gallopavo).
  • the allergen can be selected from one or more types of dairy products, e.g., Casein, bovine (Bos Taurus) and Milk, bovine (Bos Taurus).
  • dairy products e.g., Casein, bovine (Bos Taurus) and Milk, bovine (Bos Taurus).
  • the allergen can be selected from one or more types of nuts, e.g., Brazil Nut (Bertholletia excelsa); Cashew Nut (Anacardium occidental); Coconut (Cocos nucifera); Filbert/Hazelnut (Corylus Americana); Peanut (Arachis hypogaea); Pecan (Carya illinoensis); Walnut, Black (Juglans nigra); and Walnut, English (Juglans regia).
  • the allergen can be selected from one or more types of miscellaneous materials, e.g., latex, silver, or the like.
  • miscellaneous materials e.g., latex, silver, or the like.
  • inflammatory joint diseases e.g., rheumatoid arthritis, osteoarthritis, polyarthritis and gout
  • chronic inflammatory connective tissue diseases e.g., lupus erythematosus, scleroderma, Sjorgen's syndrome, poly- and dermatomyositis, vasculitis, mixed connective tissue disease (MCTD), tendonitis, synovitis, bacterial endocarditis, osteomyelitis and psoriasis
  • chronic inflammatory lung diseases e.g., chronic respiratory disease, pneumonia, fibrosing alveolitis, chronic bronchitis, chronic obstructive pulmonary disease (COPD), bronchiectasis, emphysema, silicosis and other pneumoconiosis and tuberculosis
  • an inflammatory condition or disease is selected from the group consisting of, but not limited to chronic inflammatory lung diseases (e.g., chronic respiratory disease, pneumonia, fibrosing alveolitis, chronic bronchitis, chronic obstructive pulmonary disease (COPD), bronchiectasis, emphysema, silicosis and other pneumoconiosis and tuberculosis).
  • chronic inflammatory lung diseases e.g., chronic respiratory disease, pneumonia, fibrosing alveolitis, chronic bronchitis, chronic obstructive pulmonary disease (COPD), bronchiectasis, emphysema, silicosis and other pneumoconiosis and tuberculosis.
  • COPD chronic inflammatory lung diseases
  • COPD chronic obstructive pulmonary disease
  • NSAID's non-steroidal anti-inflammatory drugs
  • Diclofenac diclofenac
  • Ibuprofen Aspirin
  • Phenylbutazone Indomethacin
  • Naproxen Naproxen
  • Piroxicam non-steroidal anti-inflammatory drugs
  • NSAID's can be effective, they are known to be associated with a number of side effects and adverse reactions. These may include gastro-intestinal problems such as dyspepsia, ulceration and haemorrhage, sleepiness, nausea or vomiting, constipation, allergic reactions and occasionally hepatoxicity. Frequently the margin between effective dose and toxic dose is quite small (i.e., 2-3-fold).
  • NSAID's as anti-inflammatory agents is standard practice in human medicine and veterinary medicine.
  • veterinary medicine there is an increasing concern about their use in food animals because of the potential for accumulation of drugs such as phenylbutazone within the food chain.
  • TLR Toll-like receptor
  • TLRs Toll-like receptors
  • TIR Toll/interleukin-1 receptor
  • the TIR adaptor protein MyD88 is required for signaling from most TLRs.
  • the MyD88-independent signaling events observed from TLR3 and TLR4 require TIR adaptor TRIF (also known as TICAM-1), with or without participation of TRAM (Yamamoto et al, 2003).
  • TIR adaptor TRIF also known as TICAM-1
  • the TLR-specific TIR adaptor signaling cascade activates receptor-specific transcription factors, such as F- ⁇ , activating protein- 1 and interferon regulatory factors (IRFs), leading to expression of inflammatory and antimicrobial genes (Akira et al, 2006; O'Neill, L.A., and Bowie, 2007; Takeda, K., and Akira, 2004).
  • a TLR agonist is any compound or substance that functions to activate a TLR directly, e.g., to induce a signaling event mediated by a TLR signal transduction pathway.
  • Suitable TLR agonists include TLR1 agonists, TLR2 agonists, TLR3 agonists, TLR4 agonists, TLR5 agonists, TLR6 agonists, TLR7 agonists, TLR8 agonists, and TLR9 agonists.
  • compositions and methods specifically involving a TLR2/6 agonist in combination with a TLR9 agonist are contemplated.
  • agonist refers to a compound that can combine with a receptor (e.g., a TLR) to produce a cellular activity.
  • a receptor e.g., a TLR
  • An agonist may be a ligand that directly binds to the receptor.
  • an agonist may combine with a receptor indirectly by, for example, (a) forming a complex with another molecule that directly binds to the receptor, or (b) otherwise results in the modification of another compound so that the other compound directly binds to the receptor.
  • An agonist may be referred to as an agonist of a particular TLR (e.g., a TLR7 agonist) or a particular combination of TLRs (e.g., a TLR 7/8 agonist—an agonist of both TLR7 and TLR8).
  • a particular TLR e.g., a TLR7 agonist
  • a particular combination of TLRs e.g., a TLR 7/8 agonist—an agonist of both TLR7 and TLR8.
  • TLR9 oligonucleotide agonist refers to a polynucleotide that stimulates or activates the TLR9 receptor.
  • CpG- ODN refers to a polynucleotide that stimulates or activates the TLR9 receptor.
  • CpG- ODN refers to a polynucleotide that stimulates or activates the TLR9 receptor.
  • CpG- ODN refers to a polynucleotide that stimulates or activates the TLR9 receptor.
  • CpG- ODN refers to a polynucleotide that stimulates or activates the TLR9 receptor.
  • CpG nucleic acid refers to a polynucleotide that stimulates or activates the TLR9 receptor.
  • CpG oligonucleotide comprises at least one 5'-CG-3' moiety, and in many embodiments comprises an unmethylated 5'-CG-3' moiety.
  • a TLR9 oligonucleotide agonist is a single- or double-stranded DNA or RNA polynucleotide having at least six nucleotide bases that may comprise, or consist of, a modified nucleotide or a sequence of modified nucleosides.
  • the 5'-CG-3' moiety of the CpG nucleic acid is part of a palindromic nucleotide sequence.
  • the 5'-CG-3' moiety of the CpG nucleic acid is part of a non-palindromic nucleotide sequence.
  • the TLR9 oligonucleotide can be an oligonucleotide analog.
  • Suitable TLR agonists include isolated, naturally-occurring TLR agonists; and synthetic TLR agonists.
  • TLR agonists isolated from a naturally-occurring source of TLR agonist are generally purified, e.g., the purified TLR agonist is at least about 80% pure, at least about 90% pure, at least about 95% pure, at least about 98% pure, at least about 99% pure, or more than 99% pure.
  • Synthetic TLR agonists are prepared by standard methods, and are generally at least about 80% pure, at least about 90% pure, at least about 95% pure, at least about 98% pure, at least about 99% pure, or more than 99% pure.
  • Suitable TLR agonists include TLR agonists that are not attached to any other compound. Suitable TLR agonists include TLR agonists that are attached, covalently or non-covalently, to a second compound. In some embodiments, a TLR agonist is attached to another compound directly. In other embodiments, a TLR agonist is attached to another compound through a linker.
  • the compound to which a TLR agonist is attached includes a carrier, a scaffold, an insoluble support, a microparticle, a microsphere, and the like.
  • Carriers include therapeutic polypeptides; polypeptides that provide for increased solubility; polypeptides that increase the half-life of the TLR agonist in a physiological medium (e.g., serum or other bodily fluid); and the like.
  • a TLR agonist will be conjugated, directly or via a linker, to a second TLR agonist.
  • the TLR agonist is a prodrug version of a TLR agonist.
  • Prodrugs are composed of a prodrug portion covalently linked to an active therapeutic agent. Prodrugs are capable of being converted to drugs (active therapeutic agents) in vivo by certain chemical or enzymatic modifications of their structure. Examples of prodrug portions are well-known in the art and can be found in the following references: Biological Approaches to the Controlled Delivery of Drugs, R. L.
  • prodrug portions are peptides, e.g., peptides that direct the TLR ligand to the site of action, and a peptide that possesses two or more free and uncoupled carboxylic acids at its amino terminus.
  • the TLR agonist is a monomeric TLR agonist.
  • the TLR agonist is multimerized, e.g., the TLR agonist is polymeric.
  • a multimerized TLR agonist is homofunctional, e.g., is composed of one type of TLR agonist.
  • the multimerized TLR agonist is a heterofunctional TLR agonist.
  • a TLR ligand is a chimeric TLR ligand (also referred to herein as a "heterofunctional" TLR ligand).
  • a chimeric TLR agonist comprises a TLR9 agonist moiety, and a TLR2 agonist moiety. The following are non-limiting examples of heterofunctional TLR agonists.
  • a chimeric TLR ligand has the following formula: (X)n-(Y)m, where X is a TLR1 agonist, TLR2 agonist, TLR3 agonist, TLR4 agonist, TLR5 agonist, TLR6 agonist, TLR7 agonist, TLR8 agonist, and TLR9 agonist, and where Y is a TLR2 agonist, TLR3 agonist, TLR4 agonist, TLR5 agonist, TLR6 agonist, TLR7 agonist, TLR8 agonist, and TLR9 agonist, and n and m are independently an integer from 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or more including all values and ranges there between.
  • X or Y is TLR9 and X or Y is TLR2/6.
  • TLR2 agonists include isolated, naturally-occurring TLR2 agonists; and synthetic TLR2 agonists.
  • TLR2 agonists isolated from a naturally- occurring source of TLR2 agonist are generally purified, e.g., the purified TLR2 agonist is at least about 80% pure, at least about 90% pure, at least about 95% pure, at least about 98%) pure, at least about 99% pure, or more than 99% pure.
  • Synthetic TLR2 agonists are prepared by standard means, and are generally at least about 80% pure, at least about 90% pure, at least about 95% pure, at least about 98% pure, at least about 99% pure, or more than 99% pure.
  • TLR2 agonists include TLR2 agonists that are not attached to any other compound.
  • TLR2 agonists include TLR2 agonists that are attached, covalently or non- covalently, to a second compound.
  • a TLR2 agonist is attached to another compound directly.
  • a TLR2 agonist is attached to another compound through a linker.
  • TLR2 agonists include synthetic triacylated and diacylated lipopeptides.
  • a non-limiting example of a TLR2 ligand is FSL-1 (a synthetic lipoprotein derived from Mycoplasma salivarium 1), Pam 3 Cys (tripalmitoyl-S-glyceryl cysteine) or S-[2,3- bis(palmitoyloxy)-(2RS)-propyl]-N-palmitoyl-(R)-cysteine, where "Parm” is "tripalmitoyl-S-glyceryl") (Aliprantis et al, 1999).
  • Derivatives of Pam 3 Cys are also suitable TLR2 agonists, where derivatives include, but are not limited to, S-[2,3- bis(palmitoyloxy)-(2-R,S)-propyl]-N-palmitoyl-(R)-Cys-(S)-Ser-(Lys)4
  • TLR2 agonist is ParmCSf PaM 2 CSK4 (dipalmitoyl-S-glyceryl cysteine-serine-(lysine)4; or Pam 2 Cys-Ser-(Lys)4) is a synthetic diacylated lipopeptide.
  • Synthetic TLRs agonists have been described in the literature. See, e.g., Kellner et al. (1992); Seifer et al. (1990); Lee et al. (2003).
  • TLR3 agonists include isolated, naturally-occurring TLR3 agonists; and synthetic TLR3 agonists.
  • TLR3 agonists isolated from a naturally- occurring source of TLR3 agonist are generally purified, e.g., the purified TLR3 agonist is at least about 80% pure, at least about 90%> pure, at least about 95%> pure, at least about 98%) pure, at least about 99%> pure, or more than 99%> pure.
  • Synthetic TLR3 agonists are prepared by standard methods, and are generally at least about 80%> pure, at least about 90%> pure, at least about 95%> pure, at least about 98%> pure, at least about 99%o pure, or more than 99%> pure.
  • TLR3 agonists include TLR3 agonists that are not attached to any other compound.
  • TLR3 agonists include TLR3 agonists that are attached, covalently or non- covalently, to a second compound.
  • a TLR3 agonist is attached to another compound directly.
  • a TLR3 agonist is attached to another compound through a linker.
  • TLR3 agonists include naturally-occurring double-stranded RNA (dsRNA); synthetic ds RNA; and synthetic dsRNA analogs; and the like (Alexopoulou et al, 2001).
  • dsRNA naturally-occurring double-stranded RNA
  • synthetic dsRNA synthetic dsRNA analogs
  • An exemplary, non-limiting example of a synthetic ds RNA analog is poly(LC).
  • TLR4 agonists include isolated, naturally-occurring TLR4 agonists; and synthetic TLR4 agonists.
  • TLR4 agonists isolated from a naturally- occurring source of TLR4 agonist are generally purified, e.g., the purified TLR4 agonist is at least about 80% pure, at least about 90% pure, at least about 95% pure, at least about 98%) pure, at least about 99% pure, or more than 99% pure.
  • Synthetic TLR4 agonists are prepared by standard methods, and are generally at least about 80% pure, at least about 90% pure, at least about 95% pure, at least about 98% pure, at least about 99%) pure, or more than 99% pure.
  • TLR4 agonists include TLR4 agonists that are not attached to any other compound. Suitable TLR4 agonists include TLR4 agonists that are attached, covalently or non-covalently, to a second compound. In some embodiments, a TLR4 agonist is attached to another compound directly. In other embodiments, a TLR4 agonist is attached to another compound through a linker. Suitable compounds to which a TLR4 agonist is attached include a carrier, a scaffold, and the like.
  • TLR4 agonists include naturally-occurring lipopolysaccharides (LPS), e.g., LPS from a wide variety of Gram negative bacteria; derivatives of naturally-occurring LPS; synthetic LPS; bacteria heat shock protein-60 (Hsp60); mannuronic acid polymers; flavolipins; teichuronic acids; S. pneumoniae pneumolysin; bacterial fimbriae, respiratory syncytial virus coat protein; and the like.
  • LPS naturally-occurring lipopolysaccharides
  • LPS naturally-occurring lipopolysaccharides
  • TLR4 agonist also include monophosphoryl lipid A-synthetic (MPLAs, Invivogen) and Phosphorylated HexaAcyl Disaccharide (PHAD, Avanti Polar Lipids), as well as other synthetic TLR4 agonists.
  • TLR 5 agonists include isolated, naturally- occurring TLR5 agonists; and synthetic TLR5 agonists.
  • TLR5 agonists isolated from a naturally-occurring source of TLR5 agonist are generally purified, e.g., the purified TLR4 agonist is at least about 80% pure, at least about 90% pure, at least about 95% pure, at least about 98%> pure, at least about 99% pure, or more than 99% pure.
  • Synthetic TLR5 agonists are prepared by standard methods, and are generally at least about 80%) pure, at least about 90% pure, at least about 95% pure, at least about 98% pure, at least about 99% pure, or more than 99% pure.
  • TLR5 agonists include TLR5 agonists that are not attached to any other compound. Suitable TLR5 agonists include TLR5 agonists that are attached, covalently or non-covalently, to a second compound. In some embodiments, a TLR5 agonist is attached to another compound directly. In other embodiments, a TLR5 agonist is attached to another compound through a linker. Suitable compounds to which a TLR5 agonist is attached include a carrier, a scaffold, and the like.
  • TLR5 agonists include a highly conserved 22 amino acid segment of flagellin as well as full length flagellin and other segments thereof.
  • TLR7 agonists include isolated, naturally-occurring TLR7 agonists; and synthetic TLR7 agonists.
  • TLR7 agonists isolated from a naturally- occurring source of TLR7 agonist are generally purified, e.g., the purified TLR7 agonist is at least about 80% pure, at least about 90% pure, at least about 95% pure, at least about 98%) pure, at least about 99% pure, or more than 99% pure.
  • Synthetic TLR7 agonists are prepared by standard means, and are generally at least about 80% pure, at least about 90% pure, at least about 95% pure, at least about 98% pure, at least about 99%) pure, or more than 99% pure.
  • TLR7 agonists include TLR7 agonists that are not attached to any other compound. Suitable TLR7 agonists include TLR7 agonists that are attached, covalently or non-covalently, to a second compound. In some embodiments, a TLR7 agonist is attached to another compound directly. In other embodiments, a TLR7 agonist is attached to another compound through a linker.
  • TLR7 ligands include imidazoquinoline compounds; guanosine analogs; pyrimidinone compounds such as bropirimine and bropirimine analogs; and the like.
  • Imidazoquinoline compounds that function as TLR7 ligands include, but are not limited to, imiquimod, (also known as Aldara, R-837, S-26308), and R-848 (also known as resiquimod, S-28463; having the chemical structure: 4-amino-2-ethoxymethyl-a, a.- dimethyl-lH-imidazol[4,5-c]quinoli-ne-l-ethanol).
  • Suitable imidazoquinoline agents include imidazoquinoline amines, imidazopyridine amines, 6,7-fused cycloalkylimidazopyridine amines, and 1,2 bridged imidazoquinoline amines. These compounds have been described in U.S. Patents 4,689,338, 4,929,624, 5,238,944, 5,266,575, 5,268,376, 5,346,905, 5,352,784, 5,389,640, 5,395,937, 5,494,916, 5,482,936, 5,525,612, 6,039,969 and 6,110,929.
  • R-848 S-28463
  • 4-amino- 2ethoxymethyl-a a-dimethyl-lH-imidazo[4,5-c]quinoline-s-i-ethanol
  • l-(2- methylpropyl)-lH-imidazo[4,5-c]quinolin-4-amine R-837 or Imiquimod
  • 4-amino-2-(ethoxymethyl)-a, a-dimethyl-6,7,8,9- tetrahydro-lH-imidazo[4,5-c]quinoline-l-ethanol hydrate see,
  • Suitable compounds include those having a 2-aminopyridine fused to a five membered nitrogen-containing heterocyclic ring.
  • Such compounds include, for example, imidazoquinoline amines including but not limited to substituted imidazoquinoline amines such as, for example, amide substituted imidazoquinoline amines, sulfonamide substituted imidazoquinoline amines, urea substituted imidazoquinoline amines, aryl ether substituted imidazoquinoline amines, heterocyclic ether substituted imidazoquinoline amines, amido ether substituted imidazoquinoline amines, sulfonamido ether substituted imidazoquinoline amines, urea substituted imidazoquinoline ethers, thioether substituted imidazoquinoline amines, and 6-, 7-, 8-, or 9-aryl or heteroaryl substituted imidazoquinoline amines; tetrahydroimidazoquinoline amines
  • Compounds include a substituted imidazoquinoline amine, a tetrahydroimidazoquinoline amine, an imidazopyridine amine, a 1,2-bridged imidazoquinoline amine, a 6,7-fused cycloalkylimidazopyridine amine, an imidazonaphthyridine amine, a tetrahydroimidazonaphthyridine amine, an oxazoloquinoline amine, a thiazoloquinoline amine, an oxazolopyridine amine, a thiazolopyridine amine, an oxazolonaphthyridine amine, and a thiazolonaphthyridine amine.
  • a substituted imidazoquinoline amine refers to an amide substituted imidazoquinoline amine, a sulfonamide substituted imidazoquinoline amine, a urea substituted imidazoquinoline amine, an aryl ether substituted imidazoquinoline amine, a heterocyclic ether substituted imidazoquinoline amine, an amido ether substituted imidazoquinoline amine, a sulfonamido ether substituted imidazoquinoline amine, a urea substituted imidazoquinoline ether, a thioether substituted imidazoquinoline amines, or a 6-, 7-, 8-, or 9-aryl or heteroaryl substituted imidazoquinoline amine.
  • Guanosine analogs that function as TLR7 ligands include certain C8- substituted and N7,C8-disubstituted guanine ribonucleotides and deoxyribonucleotides, including, but not limited to, Loxoribine (7-allyl-8- oxoguanosine), 7-thia-8-oxo-guanosine (TOG), 7-deazaguanosine, and 7- deazadeoxyguanosine (Lee et al, 2003).
  • Loxoribine (7-allyl-8- oxoguanosine
  • TOG 7-thia-8-oxo-guanosine
  • TOPOAG 7-deazaguanosine
  • 7- deazadeoxyguanosine Lee et al, 2003.
  • Bropirimine (PNU-54461), a 5-halo-6- phenyl-pyrimidinone, and bropirimine analogs are described in the literature and are also suitable for use
  • C8-substituted guanosines include but are not limited to 8-mercaptoguanosine, 8- bromoguanosine, 8-methylguanosine, 8-oxo-7,8-dihydroguanosine, C8-arylamino-2'- deoxyguanosine, C8-propynyl-guanosine, C8- and N7-substituted guanine ribonucleosides such as 7-allyl-8-oxoguanosine (loxoribine) and 7-methyl-8- oxoguanosine, 8-aminoguanosine, 8-hydroxy-2'-deoxyguanosine, and 8- hydroxy guanosine.
  • a substituted guanine TLR7 ligand is monomeric. In other embodiments, a substituted guanine TLR7 ligand is multimeric. Thus, in some embodiments, a TLR7 ligand has the formula: (B)q, where B is a substituted guanine TLR7 ligand, and q is 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10.
  • B is a substituted guanine TLR7 ligand
  • q 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10.
  • the individual TLR7 ligand monomers in a multimeric TLR7 ligand are linked, covalently or non-covalently, either directly to one another or through a linker.
  • Suitable TLR7 agonists include a TLR7 ligand as described in U.S. Patent Publication 2004/0162309.
  • a TLR7 agonist is a selective TLR7 agonist, e.g., the agonist modulates cellular activity through TLR7, but does not modulate cellular activity through TLR8.
  • TLR7-selective agonists include those shown in U. S. Patent Publication 2004/0171086.
  • TLR7 selective agonist compounds include, but are not limited to, N 1 - ⁇ 4-[4 -amino-2-(2-methoxyethyl)- 6,7,8,9-tetrahydro- 1H- imidazo[4,5-c]quinolin-l- yl]butyl ⁇ -4-fluoro-l-benzenesulfonamide, N 1 -[4-(4-amino- 2-(2-methoxy ethyl)- 1H- imidazo[4, 5-c]quinolin- 1 -yl)butyl]-4-fluoro- 1 - benzenesulfonamide, N-[4-(4-amino-2-propyl-lH-imidazo[4,5- c]quinolin-l- yl)butyl]methanesulfonamide, N- ⁇ 3-[4-amino-2-(2-methoxyethyl)-lH- imidazo[4,5- c
  • Additional suitable TLR7 selective agonists include, but are not limited to, 2- (ethoxymethyl)-l-(2-methylpropyl)-lH-imidazo[4,5-c]quinolin-4-amine (U.S. Patent 5,389,640); 2-methyl-l-[2-(3-pyridin-3-ylpropoxy)ethyl]-lH-imidazo [4,5-c]quinolin- 4-amine (WO 02/46193); N-(2- ⁇ 2-[4-amino-2-(2-methoxyethyl)-lH-imidazo[4,5- c] quinolin- l-yl]ethoxy ⁇ ethyl)-N-methylcyclohexanecarboxamide (U.S.
  • Patent Publication 2004/0171086) l-[2-(benzyloxy)ethyl]-2-methyl-lH-imidazo[4,5- c]quinolin-4-amine (WO 02/46189); N- ⁇ 8-[4-amino-2-(2-methyoxyethyl)-lH- imidazo[4,5-c]quinolin-l-yl]octyl ⁇ -N-phenylurea (U.S.
  • Patent Publication 2004/0171086 (IRM5)); 2-butyl-l-[5-(methylsulfonyl)pentyl]-lH-imidazo[4,5- c]quinolin-4-amine (WO 02/46192); N- ⁇ 3-[4-amino-2-(2-methoxyethyl)-lH- imidazo[4,5-c]quinolin-l-yl]propyl ⁇ -4-methylbenzenesulfonamide (U.S.
  • Patent 6,331,539) N-[4-(4-amino-2-ethyl-lH-imidazo[4,5-c]quinolin-l- yl)butyl]cyclohexanecar-boxamide
  • TLR7-selective agonist N-[4-(4-amino-2-ethyl-lH- imidazo[4,5-c]quinolin-l-yl)butyl-]methanesulfon- amide (Gorden et al, 2005).
  • TLR8 agonists include isolated, naturally-occurring TLR8 agonists; and synthetic TLR8 agonists.
  • TLR8 agonists isolated from a naturally- occurring source of TLR8 agonist are generally purified, e.g., the purified TLR8 agonist is at least about 80% pure, at least about 90% pure, at least about 95% pure, at least about 98%) pure, at least about 99%> pure, or more than 99%> pure.
  • Synthetic TLR8 asonists are orepared by standard methods, and are generally at least about 80%> pure, at least about 90% pure, at least about 95% pure, at least about 98%> pure, at least about 99% pure, or more than 99% pure.
  • TLR8 agonists include TLR8 agonists that are not attached to any other compound.
  • TLR8 agonists include TLR8 agonists that are attached, covalently or non- covalently, to a second compound.
  • a TLR8 agonist is attached to another compound directly.
  • a TLR8 agonist is attached to another compound through a linker.
  • TLR8 agonists include, but are not limited to, compounds such as R-848, and derivatives and analogs thereof.
  • Suitable TLR8 agonists include compounds having a 2-aminopyridine fused to a five membered nitrogen-containing heterocyclic ring.
  • Such compounds include, for example, imidazoquinoline amines including but not limited to substituted imidazoquinoline amines such as, for example, amide substituted imidazoquinoline amines, sulfonamide substituted imidazoquinoline amines, urea substituted imidazoquinoline amines, aryl ether substituted imidazoquinoline amines, heterocyclic ether substituted imidazoquinoline amines, amido ether substituted imidazoquinoline amines, sulfonamido ether substituted imidazoquinoline amines, urea substituted imidazoquinoline ethers, thioether substituted imidazoquinoline amines, and 6-, 7-, 8-, or 9-aryl or heteroaryl substituted imidazoquinoline amines; tetrahydroimidazoquinoline amines including but not limited to amide substituted tetrahydroimidazoquinoline amines, sulfonamide substituted t
  • the TLR8 agonist is an amide substituted imidazoquinoline amine.
  • the TLR8 agonist is a sulfonamide substituted imidazoquinoline amine.
  • the TLR8 agonist is a urea substituted imidazoquinoline amine.
  • the TLR8 agonist is an aryl ether substituted imidazoquinoline amine.
  • the TLR8 agonist is a heterocyclic ether substituted imidazoquinoline amine.
  • the TLR8 agonist is an amido ether substituted imidazoquinoline amine.
  • the TLR8 agonist is a sulfonamido ether substituted imidazoquinoline amine. In another alternative embodiment, the TLR8 agonist is a urea substituted imidazoquinoline ether. In another alternative embodiment, the TLR8 agonist is a thioether substituted imidazoquinoline amine. In another alternative embodiment, the TLR8 agonist is a 6-, 7-, 8-, or 9-aryl or heteroaryl substituted imidazoquinoline amine.
  • the TLR8 agonist is an amide substituted tetrahydroimidazoquinoline amine. In another alternative embodiment, the TLR8 agonist is a sulfonamide substituted tetrahydroimidazoquinoline amine. In another alternative embodiment, the TLR8 agonist is a urea substituted tetrahydroimidazoquinoline amine. [00105] In another alternative embodiment, the TLR8 agonist is an aryl ether substituted tetrahydroimidazoquinoline amine. In another alternative embodiment, the TLR8 agonist is a heterocyclic ether substituted tetrahydroimidazoquinoline amine.
  • the TLR8 agonist is an amido ether substituted tetrahydroimidazoquinoline amine. In another alternative embodiment, the TLR8 agonist is a sulfonamido ether substituted tetrahydroimidazoquinoline amine. In another alternative embodiment, the TLR8 agonist is a urea substituted tetrahydroimidazoquinoline ether. In another alternative embodiment, the TLR8 agonist is a thioether substituted tetrahydroimidazoquinoline amine.
  • the TLR8 agonist is an amide substituted imidazopyridine amines. In another alternative embodiment, the TLR8 agonist is a sulfonamide substituted imidazopyridine amine. In another alternative embodiment, the TLR8 agonist is a urea substituted imidazopyridine amine. In another alternative embodiment, the TLR8 agonist is an aryl ether substituted imidazopyridine amine. In another alternative embodiment, the TLR8 agonist is a heterocyclic ether substituted imidazopyridine amine. In another alternative embodiment, the TLR8 agonist is an amido ether substituted imidazopyridine amine.
  • the TLR8 agonist is a sulfonamido ether substituted imidazopyridine amine. In another alternative embodiment, the TLR8 agonist is a urea substituted imidazopyridine ether. In another alternative embodiment, the TLR8 agonist is a thioether substituted imidazopyridine amine.
  • the TLR8 agonist is a 1,2-bridged imidazoquinoline amine. In another alternative embodiment, the TLR8 agonist is a 6,7- fused cycloalkylimidazopyridine amine.
  • the TLR8 agonist is an imidazonaphthyridine amine. In another alternative embodiment, the TLR8 agonist is a tetrahydroimidazonaphthyridine amine. In another alternative embodiment, the TLR8 agonist is an oxazoloquinoline amine. In another alternative embodiment, the TLR8 agonist is a thiazoloquinoline amine. In another alternative embodiment, the TLR8 agonist is an oxazolopyridine amine. In another alternative embodiment, the TLR8 agonist is a thiazolopyridine amine. In another alternative embodiment, the TLR8 agonist is an oxazolonaphthyridine amine. In another alternative embodiment, the TLR8 agonist is a thiazolonaphthyridine amine.
  • the TLR8 agonist is a IH-imidazo dimer fused to a pyridine amine, quinoline amine, tetrahydroquinoline amine, naphthyridine amine, or a tetrahydronaphthyridine amine.
  • the TLR8 agonist is a selective TLR8 agonist, e.g., the agonist modulates cellular activity through TLR8, but does not modulate cellular activity through TLR7.
  • TLR8-selective agonists include those in U.S. Patent Publication 2004/0171086.
  • Such TLR8 selective agonist compounds include, but are not limited to, the compounds shown in U. S. Patent Publication No.
  • 2004/0171086 that include N- ⁇ 4- [4-amino-2-(2-methoxy ethyl)- 1 H-imidazo[4, 5 -c] quinolin- 1 - yl]butyl ⁇ quinolin-3-carboxamide, N- ⁇ 4-[4-amino-2-(2-methoxyethyl)-lH- imidazo[4,5-c]quinolin-l-yl]butyl ⁇ quinoxoline-2-carboxamide, and N-[4-(4-amino-2- propyl-lH-imidazo[4,5-c]quinolin-l-yl)butyl]morpholine-4-carboxamide.
  • TLR8- selective agonists include, but are not limited to, 2- propylthiazolo[4,5-c]quinolin-4-amine (U. S. Patent 6, 1 10,929); N ⁇ 2-(4-amino-2- butyl-lH-imidazo[4,5-c][l,5]naphthridin-l -yl)ethyl] ⁇ 2-amino-4-methylpentanamide (U.S. Patent 6, 194,425); N 1 -[4-(4-amino-lH-imidazo[4,5-c]quinolin-l-yl)butyl]-2- phenoxy-benzamide (U.S.
  • Patent 6,451,810) N 1 -[2-(4-amino-2-butyl-lH-imidazo[4,5- c]quinolin-l-yl)ethyl]-l-propa-nesulfonamide (U. S. Patent 6,331,539); N- ⁇ 2-[2-(4- amino-2-ethyl-lH-imidazo[4,5-c]quinolin-l-yl)ethyoxy]ethyl ⁇ -N' ⁇ phenylurea (U. S.
  • Patent Publication 2004/0171086) l- ⁇ 4-[3,5-dichlorophenyl)thio]butyl ⁇ -2-ethyl-lH- imidazo[4,5-c]quinolin-4- amine (U.S. Patent Publication 2004/0171086); N- ⁇ 2-[4- amino-2-(ethoxymethyl)-lH-imidazo[4,5-c]quinolin-l-yl]ethyl ⁇ -N'-(3- cyanophenyl)urea (WO 00/76518 and U. S. Patent Publication No.
  • TLR8- selective agonists include the compounds in U.S. Patent Publication No. 2004/0171086. Also suitable for use is the compound 2- propylthiazolo-4,5-c]quinolin-4-amine (Gorden et al, 2005 supra).
  • TLR9 agonists include isolated, naturally-occurring TLR9 agonists; and synthetic TLR9 agonists.
  • TLR9 agonists isolated from a naturally- occurring source of TLR9 agonist are generally purified, e.g., the purified TLR9 agonist is at least about 80% pure, at least about 90% pure, at least about 95% pure, at least about 98%) pure, at least about 99% pure, or more than 99% pure.
  • Synthetic TLR9 agonists are prepared by standard methods, and are generally at least about 80% pure, at least about 90% pure, at least about 95% pure, at least about 98% pure, at least about 99%) pure, or more than 99% pure.
  • TLR9 agonists include TLR9 agonists that are not attached to any other compound.
  • TLR9 agonists include TLR9 agonists that are attached, covalently or non- covalently, to a second compound.
  • a TLR9 agonist is attached to another compound directly.
  • a TLR9 agonist is attached to another compound through a linker.
  • TLR9 agonists include nucleic acids comprising the sequence 5'-CG-3' (a "CpG nucleic acid” or "ODN”), in certain aspects C is unmethylated.
  • polynucleotide and “nucleic acid,” as used interchangeably herein in the context of TLR9 ligand molecules, refer to a polynucleotide of any length, and encompasses, inter alia, single- and double- stranded oligonucleotides (including deoxyribonucleotides, ribonucleotides, or both), modified oligonucleotides, and oligonucleosides, alone or as part of a larger nucleic acid construct, or as part of a conjugate with a non-nucleic acid molecule such as a polypeptide.
  • oligonucleotides including deoxyribonucleotides, ribonucleotides, or both
  • modified oligonucleotides and oligonucleosides
  • a TLR9 ligand may be, for example, single-stranded DNA (ssDNA), double-stranded DNA (dsDNA), single-stranded RNA (ssRNA) or double-stranded RNA (dsRNA).
  • TLR9 ligands also encompasses crude, detoxified bacterial ⁇ e.g., mycobacterial) RNA or DNA, as well as enriched plasmids enriched for a TLR9 ligand.
  • a "TLR9 ligand-enriched plasmid" refers to a linear or circular plasmid that comprises or is engineered to comprise a greater number of CpG motifs than normally found in mammalian DNA.
  • Type A CpG ODNs are characterized by a phosphodiester central CpG-containing palindromic motif and a phosphorothioate 3' poly-G string.
  • Type B CpG ODNs contain a phosphorothioate backbone with one or more CpG dinucleotides. They strongly activate B cells but stimulate weakly IFN-a secretion.
  • Type C CpG ODNs combine features of both types A and B. They contain a phosphorothioate backbone and a CpG-containing palindromic motif. Type C CpG ODNs induce strong IFN-a production from pDC and B cell stimulation.
  • oligonucleotides include, but are not limited to, modifications of the 3 ⁇ or 5 ⁇ group, modifications of the nucleotide base, modifications of the sugar component, and modifications of the phosphate group.
  • a TLR9 ligand may comprise at least one nucleoside comprising an L-sugar.
  • the L-sugar may be deoxyribose, ribose, pentose, deoxypentose, hexose, deoxyhexose, glucose, galactose, arabinose, xylose, lyxose, or a sugar "analog" cyclopentyl group.
  • the L-sugar may be in pyranosyl or furanosyl form.
  • TLR9 ligands generally do not provide for, nor is there any requirement that they provide for, expression of any amino acid sequence encoded by the polynucleotide, and thus the sequence of a TLR9 ligand may be, and generally is, non-coding.
  • TLR9 ligands may comprise a linear double or single-stranded molecule, a circular molecule, or can comprise both linear and circular segments.
  • TLR9 ligands may be single- stranded, or may be completely or partially double-stranded.
  • a TLR9 ligand for use in a subject method is an oligonucleotide, e.g., consists of a sequence of from about 5 nucleotides to about 200 nucleotides, from about 10 nucleotides to about 100 nucleotides, from about 12 nucleotides to about 50 nucleotides, from about 15 nucleotides to about 25 nucleotides, from 20 nucleotides to about 30 nucleotides, from about 5 nucleotides to about 15 nucleotides, from about 5 nucleotides to about 10 nucleotides, or from about 5 nucleotides to about 7 nucleotides in length.
  • a TLR9 ligand that is less than about 15 nucleotides, less than about 12 nucleotides, less than about 10 nucleotides, or less than about 8 nucleotides in length is associated with a larger molecule.
  • a TLR9 ligand does not provide for expression of a peptide or polypeptide in a eukaryotic cell, e.g., introduction of a TLR9 ligand into a eukaryotic cell does not result in production of a peptide or polypeptide, because the TLR9 ligand does not provide for transcription of an mRNA encoding a peptide or polypeptide.
  • a TLR9 ligand lacks promoter regions and other control elements necessary for transcription in a eukaryotic cell.
  • a TLR9 ligand can be isolated from a bacterium, e.g., separated from a bacterial source; produced by synthetic methods (e.g., produced by standard methods for chemical synthesis of polynucleotides); produced by standard recombinant methods, then isolated from a bacterial source; or a combination of the foregoing.
  • a TLR9 ligand is purified, e.g., is at least about 80%, at least about 90%, at least about 95%, at least about 98%, at least about 99%, or more, e.g., 99.5%, 99.9%, or more, pure.
  • the TLR9 ligand is chemically synthesized, then purified.
  • a TLR9 ligand is part of a larger nucleotide construct (e.g., a plasmid vector, a viral vector, or other such construct).
  • a plasmid vector e.g., a plasmid vector, a viral vector, or other such construct.
  • plasmid and viral vector are known in the art, and need not be elaborated upon here. A large number of such vectors have been described in various publications, including, e.g., Current Protocols in Molecular Biology, (1987, and updates).
  • a TLR9 ligand used in a subject composition comprises at least one unmethylated CpG motif.
  • the relative position of any CpG sequence in a polynucleotide in certain mammalian species is 5'-CG-3'(z ' .e., the C is in the 5' position with respect to the G in the 3' position).
  • a TLR9 ligand comprises a central palindromic core sequence comprising at least one CpG sequence, where the central palindromic core sequence contains a phosphodiester backbone, and where the central palindromic core sequence is flanked on one or both sides by phosphorothioate backbone-containing polyguanosine sequences.
  • a TLR9 ligand comprises one or more TCG sequences at or near the 5' end of the nucleic acid; and at least two additional CG dinucleotides.
  • the at least two additional CG dinucleotides are spaced three nucleotides, two nucleotides, or one nucleotide apart.
  • the at least two additional CG dinucleotides are contiguous with one another.
  • Exemplary consensus CpG motifs of TLR9 ligands useful herein include, but are not necessarily limited to: 5'-Purine-Purine-(C)-(G)-Pyrimidine-Pyrimidine-3', in which the TLR9 ligand comprises a CpG motif flanked by at least two purine nucleotides (e.g., GG, GA, AG, AA, II, etc.,) and at least two pyrimidine nucleotides (CC, TT, CT, TC, UU, etc.); 5'-Purine-TCG-Pyrimidine-Pyrimidine-3 '; 5'-TCG-N-N- 3'; where N is any base; 5'-Nx(CG)nNy, where N is any base, where x and y are independently any integer from 0 to 200, e.g., 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 1 1-15, 16- 20, 21-25, 25-30, 30-50, 50
  • N is any base
  • x and y are independently any integer from 0 to 200, e.g., 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 1 1-15, 16-20, 21-25, 25-30, 30-50, 50-75, 75-100, 100-150, or 150- 200
  • n is any integer that is 1 or greater, e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or greater.
  • a nucleic acid TLR9 ligand comprises a sequence of the formula: 5'- Nm-(TCG)n-Np-3', where N is any nucleotide, where m is zero to 5, and where n is any integer that is 1 or greater, where p is four or greater, and where the sequence N-N-N- N comprises at least two CG dinucleotides that are either contiguous with each other or are separated by one nucleotide, two nucleotides, or three nucleotides
  • a nucleic acid TLR9 ligand comprises a sequence of the formula: 5'Nm-(TCG)n-Np-3', where N is any nucleotide, where m is zero, one, two, or three, where n is any integer that is 1 or greater, and where p is one, two, three, or four
  • the core structure of a TLR9 ligand may be flanked upstream and/or downstream by any number or composition of nucleotides or nucleosides.
  • the core sequence of a TLR9 ligand is at least 6 bases or 8 bases in length, and the complete TLR9 ligand (core sequences plus flanking sequences 5', 3' or both) is usuallv between 6 bases or 8 bases, and up to about 200 bases in length.
  • DNA-based TLR9 ligands include, but are not necessarily limited to, polynucleotides comprising one or more of the following nucleotide sequences: AGCGCT, AGCGCC, AGCGTT, AGCGTC, AACGCT, AACGCC, AACGTT, AACGTC, GGCGCT, GGCGCC, GGCGTT, GGCGTC, GACGCT, GACGCC, GACGTT, GACGTC, GTCGTC, GTCGCT, GTCGTT, GTCGCC, ATCGTC, ATCGCT, ATCGTT, ATCGCC, TCGTCG, and TCGTCGTCG.
  • Additional TLR9 ligands include, but are not necessarily limited to, polynucleotides comprising one or more of the following nucleotide sequences: TCGXXXX, TCGAXXX, XTCGXXX, XTCGAXX, TCGTCGA, TCGACGT, TCGAACG, TCGAGAT, TCGACTC, TCGAGCG, TCGATTT, TCGCTTT, TCGGTTT, TCGTTTT, TCGTCGT, ATCGATT, TTCGTTT, TTCGATT, ACGTTCG, AACGTTC, TGACGTT, TGTCGTT, TCGXXX, TCGAXX, TCGTCG, AACGTT, ATCGAT, GTCGTT, GACGTT, TCGXX, TCGAX, TCGAT, TCGTT, TCGTC, TCGA, TCGT, TCGX, and TCG (where "X" is any nucleotide).
  • DNA-based TLR9 ligands include, but are not necessarily limited to, polynucleotides comprising the following octameric nucleotide sequences: AGCGCTCG, AGCGCCCG, AGCGTTCG, AGCGTCCG, AACGCTCG, AACGCCCG, AACGTTCG, AACGTCCG, GGCGCTCG, GGCGCCCG, GGCGTTCG, GGCGTCCG, GACGCTCG, GACGCCCG, GACGTTCG, and GACGTCCG.
  • a TLR9 ligand can comprise one or more of any of the above CpG motifs.
  • a TLR9 ligand can comprise a single instance or multiple instances (e.g., 2, 3, 4, 5 or more) of the same CpG motif.
  • a TLR9 ligand can comprise multiple CpG motifs (e.g., 2, 3, 4, 5 or more) where at least two of the multiple CpG motifs have different consensus sequences, or where all CpG motifs in the TLR9 ligand have different consensus sequences.
  • a TLR9 ligand may or may not include palindromic regions.
  • a palindrome may extend only to a CpG motif, if present, in the core hexamer or octamer sequence, or may encompass more of the hexamer or octamer sequence as well as flanking nucleotide sequences.
  • the TLR9 agonists can be an TLR9 oligonucleotide agonist, including but not limited to type A CpG oligodeoxynucleotide, a type B CpG oligodeoxynucleotide, a type C CpG oligodeoxynucleotides or other oligodeoxynucleotides.
  • the TLR9 agonist is a type C oligodeoxynucleotide (ODN), such as ODN2395 (5'-tcgtcgttttcggcgcgcgccg-3' (22 mer)SEQ ID NO: ) or ODNM362 (5'-tcgtcgtcgttcgaacgacgttgat-3' (25 mer) SEQ ID NO: ) or ODN10101 (5'-tcgtcgttttcgcgcgcgcgcg-3' SEQ ID NO: ) or 9 mer (5'- cgcgaagcg-3' SEQ ID NO: ) or H-Tel 22 (5'-agggttagggttagggttaggg-3' SEQ ID NO: ) or analog thereof.
  • ODN2395 5'-tcgtcgttttcggcgcgcgcgcg-3' (22 mer)
  • a TLR9 ligand is multimeric.
  • a multimeric TLR9 ligand comprises two, three, four, five, six, seven, eight, nine, ten, or more individual (monomelic) nucleic acid TLR9 ligands, as described above, linked via non-covalent bonds, linked via covalent bonds, and either linked directly to one another, or linked via one or more spacers. Suitable spacers include nucleic acid and non-nucleic acid molecules, as long as they are biocompatible.
  • multimeric TLR9 ligand comprises a linear array of monomeric TLR9 ligands.
  • a multimeric TLR9 ligand is a branched, or dendrimeric, array of monomeric TLR9 ligands.
  • a multimeric TLR9 ligand has the general structure (Xl)n(X2)n where X is a nucleic acid TLR9 ligand as described above, and having a length of from about 6 nucleotides to about 200 nucleotides, e.g., from about 6 nucleotides to about 8 nucleotides, from about 8 nucleotides to about 10 nucleotides, from about 10 nucleotides to about 12 nucleotides, from about 12 nucleotides to about 15 nucleotides, from about 15 nucleotides to about 20 nucleotides, from about 20 nucleotides to about 25 nucleotides, from about 25 nucleotides to about 30 nucleotides, from about 30 nucleotides to about 40 nucleotides, from about 40 nucleotides to about 50 nucleotides, from about 50 nucleotides to about 60 nucleotides, from about 60 nucleotides, from about 60
  • X and X2 differ in nucleotide sequence from one another by at least one nucleotide, and may differ in nucleotide sequence from one another by two, three, four, five, six, seven, eight, nine, ten, or more bases.
  • a subject multimeric TLR9 ligand comprises a TLR9 ligand separated from an adjacent TLR9 ligand by a spacer.
  • a spacer is a non-TLR9 ligand nucleic acid.
  • a spacer is a non-nucleic acid moiety. Suitable spacers include those described in U.S. Patent Publication 20030225016.
  • a TLR9 ligand is multimerized using any known method.
  • TLR9 ligand modifications A TLR9 ligand suitable for use in a subject composition can be modified in a variety of ways.
  • a TLR9 ligand can comprise backbone phosphate group modifications (e.g., methylphosphonate, phosphorothioate, phosphoroamidate and phosphorodithioate intemucleotide linkages), which modifications can, for example, enhance their stability in vivo, making them particularly useful in therapeutic applications.
  • a particularly useful phosphate group modification is the conversion to the phosphorothioate or phosphorodithioate forms of a nucleic acid TLR9 ligand.
  • Phosphorothioates and phosphorodithioates are more resistant to degradation in vivo than their unmodified oligonucleotide counterparts, increasing the half-lives of the TLR9 ligands and making them more available to the subject being treated.
  • TLR9 ligands include TLR9 ligands having modifications at the 5' end, the 3' end, or both the 5' and 3' ends.
  • the 5' and/or 3' end can be covalently or non-covalently associated with a molecule (either nucleic acid, non- nucleic acid, or both) to, for example, increase the bio-availability of the TLR9 ligand, increase the efficiency of uptake where desirable, facilitate delivery to cells of interest, and the like.
  • Molecules for conjugation to a TLR9 ligand include, but are not necessarily limited to, cholesterol, phospholipids, fatty acids, sterols, oligosaccharides, polypeptides (e.g., immunoglobulins), peptides, antigens (e.g., peptides, small molecules, etc.), linear or circular nucleic acid molecules (e.g., a plasmid), insoluble supports, therapeutic polypeptides, and the like.
  • Therapeutic polypeptides that are suitable for attachment to a TLR9 agonist include, but are not limited to, a dendritic cell growth factor (e.g., GM-CSF); a cytokine; an interferon (e.g., an IFN-a, an IFN- ⁇ , etc.); a T F-a antagonist; and the like.
  • a dendritic cell growth factor e.g., GM-CSF
  • a cytokine e.g., a cytokine
  • an interferon e.g., an IFN-a, an IFN- ⁇ , etc.
  • T F-a antagonist e.g., T F-a antagonist
  • a TLR9 ligand is in some embodiments linked (e.g., conjugated, covalently linked, non-covalently associated with, or adsorbed onto) an insoluble support.
  • An exemplary, non-limiting example of an insoluble support is cationic poly(D,L-lactide- co-glycolide).
  • TLR9 ligand conjugates include conjugates comprising a nucleic acid TLR9 ligand.
  • a polypeptide e.g., a therapeutic polypeptide
  • linker molecules are known in the art and can be used in the conjugates.
  • the linkage from the peptide to the oligonucleotide may be through a peptide reactive side chain, or the N- or C-terminus of the peptide.
  • Linkage from the oligonucleotide to the peptide may be at either the 3' or 5' terminus, or internal.
  • a linker may be an organic, inorganic, or semi-organic molecule, and may be a polymer of an organic molecule, an inorganic molecule, or a co-polymer comprising both inorganic and organic molecules.
  • the linker molecules are generally of sufficient length to permit oligonucleotides and/or polynucleotides and a linked polypeptide to allow some flexible movement between the oligonucleotide and the polypeptide.
  • the linker molecules are generally about 6-50 atoms long.
  • the linker molecules may also be, for example, aryl acetylene, ethylene glycol oligomers containing 2-10 monomer units, diamines, diacids, amino acids, or combinations thereof.
  • Other linker molecules which can bind to oligonucleotides may be used in light of this disclosure.
  • the inventors have used the mouse as a model for studying the stimulation by compositions described herein.
  • the effects of single and repetitive exposure of a subject to a composition described herein have been determined and no obvious gross pathology, such as premature death, weight loss, or behavioral changes have been observed.
  • compositions described herein can be delivered and have effect quickly and easily. Also, the compositions can be produced economically in large quantities and easily stored, as well as easily transported by a person outside of a hospital setting.
  • compositions disclosed herein may be administered via the respiratory system of a subject.
  • the compositions are deposited in the lung by methods and devices known in the art.
  • Compositions may be prepared in water suitably mixed with a surfactant, such as hydroxypropylcellulose.
  • Dispersions may also be prepared in glycerol, liquid polyethylene glycols and mixtures thereof, and in oils. Under ordinary conditions of storage and use, these preparations contain a preservative to prevent the growth of microorganisms.
  • the pharmaceutical forms suitable for inhalation include sterile aqueous solutions or dispersions and sterile powders for the extemporaneous preparation of sterile inhalable solutions or dispersions.
  • the carrier can be a solvent or dispersion medium containing, for example, water, ethanol, polyol (e.g., glycerol, propylene glycol, and liquid polyethylene glycol, and the like), suitable mixtures thereof, and/or vegetable oils.
  • the prevention of the action of microorganisms can be brought about by various antibacterial and antifungal agents, for example, parabens, chlorobutanol, phenol, sorbic acid, thimerosal, and the like.
  • Sterile compositions are prepared by incorporating the active components in the required amount in the appropriate solvent with various other ingredients enumerated above, as required, followed by, for example, filtered sterilization.
  • dispersions are prepared by incorporating the various sterilized active ingredients into a sterile vehicle which contains the basic dispersion medium and the required other ingredients from those enumerated above.
  • some methods of preparation are vacuum- drying and freeze-drying techniques which yield a powder of the active ingredient plus anv additional desired ingredient from a previously sterile-filtered solution.
  • Pulmonary/respiratory drug delivery can be implemented by different approaches, including liquid nebulizers, aerosol-based metered dose inhalers (MDI's), sprayers, dry powder dispersion devices and the like.
  • liquid nebulizers including aerosol-based metered dose inhalers (MDI's), sprayers, dry powder dispersion devices and the like.
  • MDI's aerosol-based metered dose inhalers
  • sprayers dry powder dispersion devices and the like.
  • dry powder dispersion devices are well known to those of skill in the art, as indicated by U.S. Patents 6,797,258, 6,794,357, 6,737,045, and 6,488,953, all of which are incorporated by reference.
  • at least one pharmaceutical composition can be delivered by any of a variety of inhalation or nasal devices known in the art for administration of a therapeutic agent by inhalation. Other devices suitable for directing pulmonary or nasal administration are also known in the art.
  • At least one pharmaceutical composition is delivered in a particle size effective for reaching the lower airways of the lung or sinuses.
  • Some specific examples of commercially available inhalation devices suitable for the practice of methods are TurbohalerTM (Astra), Rotahaler® (Glaxo), Diskus® (Glaxo), SpirosTM inhaler (Dura), devices marketed by Inhale Therapeutics, AERxTM (Aradigm), the Ultravent® nebulizer (Mallinckrodt), the Acorn II® nebulizer (Marquest Medical Products), the Ventolin® metered dose inhaler (Glaxo), the Spinhaler® powder inhaler (Fisons), or the like.
  • All such inhalation devices can be used for the administration of a pharmaceutical composition in an aerosol.
  • aerosols may comprise either solutions (both aqueous and non aqueous) or solid particles.
  • Metered dose inhalers typically use a propellant gas and require actuation during inspiration. See, e.g., WO 98/35888; WO 94/16970.
  • Dry powder inhalers use breath-actuation of a mixed powder. See U.S. Patents 5,458, 135; 4,668,218; PCT publications WO 97/25086; WO 94/08552; WO 94/06498; and European application EP 0237507, each of which is incorporated herein by reference in their entirety.
  • Nebulizers produce aerosols from solutions, while metered dose inhalers, dry powder inhalers, and the like generate small particle aerosols.
  • Suitable formulations for administration include, but are not limited to nasal spray or nasal drops, and may include aqueous or oily solutions of a StIR composition.
  • a spray comprising a pharmaceutical composition can be produced by forcing a suspension or solution of a composition through a nozzle under pressure. The nozzle size and configuration, the applied pressure, and the liquid feed rate can be chosen to achieve the desired output and particle size.
  • An electrospray can be produced, for example, by an electric field in connection with a capillary or nozzle feed.
  • a pharmaceutical composition can be administered by a nebulizer such as a jet nebulizer or an ultrasonic nebulizer.
  • a nebulizer such as a jet nebulizer or an ultrasonic nebulizer.
  • a compressed air source is used to create a high-velocity air jet through an orifice.
  • a low-pressure region is created, which draws a composition through a capillary tube connected to a liquid reservoir.
  • the liquid stream from the capillary tube is sheared into unstable filaments and droplets as it exits the tube, creating the aerosol.
  • a range of configurations, flow rates, and baffle types can be employed to achieve the desired performance characteristics from a given jet nebulizer.
  • an ultrasonic nebulizer high-frequency electrical energy is used to create vibrational, mechanical energy, typically employing a piezoelectric transducer. This energy is transmitted to the composition creating an aerosol.
  • a propellant In a metered dose inhaler (MDI), a propellant, a composition, and any excipients or other additives are contained in a canister as a mixture with a compressed gas. Actuation of the metering valve releases the mixture as an aerosol.
  • MDI metered dose inhaler
  • compositions for use with a metered-dose inhaler device will generally include a finely divided powder containing a composition described herein as a suspension in a non-aqueous medium, for example, suspended in a propellant with the aid of a surfactant.
  • the propellant can be any conventional material employed for this purpose such as chlorofluorocarbon, a hydrochlorofluorocarbon, a hydrofluorocarbon, or a hydrocarbon including trichlorofluoromethane, dichlorodifluoromethane, dichlorotetrafluoroethanol and 1, 1,1,2-tetrafluoroethane, HFA-134a (hydrofluroalkane-134a), HFA-227 (hydrofluroalkane-227), or the like.
  • Methods may involve administering to the patient or subject at least or at most 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or more doses of a therapeutic composition.
  • a dose may be a composition comprising about, at least about, or at most about 0.01, 0.02, 0.03, 0.04, 0.05, 0.06, 0.07, 0.08, 0.09, 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, 1.0, 1.1, 1.2, 1.3, 1.4, 1.5, 1.6, 1.7, 1.8, 1.9, 2.0, 2.1, 2.2, 2.3, 2.4, 2.5, 2.6, 2.7, 2.8, 2.9, 3.0, 3.1, 3.2, 3.3, 3.4, 3.5, 3.6, 3.7.
  • a dose may be administered on an as needed basis or every 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 18, or 24 hours (or any range derivable therein) or 1, 2, 3, 4, 5, 6, 7, 8, 9, or times per day (or any range derivable therein).
  • a dose may be first administered before or after signs of an infection are exhibited or felt by a patient or after a clinician evaluates the patient for an infection.
  • the patient is administered a first dose of a regimen 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12 hours (or any range derivable therein) or 1, 2, 3, 4, or 5 days after the patient experiences or exhibits signs or symptoms of an infection (or any range derivable therein).
  • the patient may be treated for 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or more days (or any range derivable therein) or until symptoms of an infection have disappeared or been reduced or after 6, 12, 18, or 24 hours or 1, 2, 3, 4, or 5 days after symptoms of an infection have disappeared or been reduced.
  • compositions comprising two TLR agonists the ratio of the two TLR agonists may be about 1 : 1, 2: 1, 3 : 1, 4: 1, 5: 1, 6: 1, 7: 1, 8: 1, 9: 1, 10: 1, 11 : 1, 12: 1, 13 : 1, 14: 1, 15: 1, 20: 1, 30; 1, 40: 1, 50: 1, 60: 1, 70: 1, 80: 1, 90: 1, 100: 1 or more, or any range derivable therein.
  • the TLR agonists are TLR2/6 and TLR9 agonists (or vice versa).
  • Treatment with a nebulizer may be at least or at most about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 110, or 120 minutes in length (or any range derivable therein).
  • the nebulizer reservoir may contain a solution that comprises about, at least about or at most about 0.1, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 110, 120, 130, 140, 150, 160, 170, 180, 190, 200, 210, 220
  • the volume that is administered in each dose may be about, at least about, or at most about 0.01, 0.02, 0.03, 0.04, 0.05, 0.06, 0.07, 0.08, 0.09, 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, 1.0, 1.1, 1.2, 1.3, 1.4, 1.5, 1.6, 1.7, 1.8, 1.9, 2.0, 2.1, 2.2, 2.3, 2.4, 2.5, 2.6, 2.7, 2.8, 2.9, 3.0, 3.1, 3.2, 3.3, 3.4, 3.5, 3.6, 3.7.
  • carrier includes any and all solvents, dispersion media, vehicles, coatings, diluents, antibacterial and antifungal agents, isotonic and absorption delaying agents, buffers, carrier solutions, suspensions, colloids, and the like.
  • solvents dispersion media, vehicles, coatings, diluents, antibacterial and antifungal agents, isotonic and absorption delaying agents, buffers, carrier solutions, suspensions, colloids, and the like.
  • the use of such media and agents for pharmaceutical active substances is well known in the art. Except insofar as any conventional media or agent is incompatible with the active ingredient, its use in the therapeutic compositions is contemplated. Supplementary active ingredients can also be incorporated into the compositions.
  • compositions that do not produce an allergic or similar untoward reaction when administered to a subject.
  • preparation of an aqueous composition that contains a polypeptide or peptide as an active ingredient is well understood in the art.
  • compositions and methods may be used in the context of a number of therapeutic or prophylactic applications.
  • second therapy e.g., anti-allergy therapy.
  • the therapy involving TLR agonists is contemplated for use after the subject has tried traditional therapy with little or limited success.
  • Administration of a composition to a subject will follow general protocols for the administration via the respiratory system, and the general protocols for the administration of a particular secondary therapy will also be followed, taking into account the toxicity, if any, of the treatment. It is expected that the treatment cycles would be repeated as necessary.
  • various standard therapies, as well as vaccination may be applied in combination with the described therapies.
  • an anti -inflammatory agent may be used in combination with a TLR or O/P composition.
  • a patient is treated with an asthma therapeutic, such as one or more fast acting medicines to treat acute symptoms and/or a long term control medicine.
  • fast acting medicines include but are not limited to beta2-adrenoceptor agonists (SABA), such as salbutamol or albuterol, anticholinergic medications such as ipratropium bromide, and adrenergic agonists such as epinephrine.
  • SABA beta2-adrenoceptor agonists
  • anticholinergic medications such as ipratropium bromide
  • adrenergic agonists such as epinephrine
  • long term control medications include, but are not limited to, glucocorticoids, long acting beta adrenoceptor agonists (LABA), leukotriene antagonists, or mast cell stabilizers.
  • Steroidal anti -inflammatories for use herein include, but are not limited to fluticasone, beclomethasone, any pharmaceutically acceptable derivative thereof, and any combination thereof.
  • a pharmaceutically acceptable derivative includes any salt, ester, enol ether, enol ester, acid, base, solvate or hydrate thereof. Such derivatives may be prepared by those of skill in the art using known methods for such derivatization.
  • Fluticasone - Fluticasone propionate is a synthetic corticosteroid and has the empirical formula C25H31F3O5S. It has the chemical name S-(fluromethyl)6a,9- difluoro- 11 ⁇ - 17-dihydroxy- 16a-methyl-3 -oxoandrosta- 1 ,4-diene- 17 ⁇ - carbothioate, 17-propionate.
  • Fluticasone propionate is a white to off-white powder with a molecular weight of 500.6 and is practically insoluble in water, freely soluble in dimethyl sulfoxide and dimethylformamide, and slightly soluble in methanol and 95% ethanol.
  • formulations may comprise a steroidal anti -inflammatory (e.g., fluticasone propionate)
  • a steroidal anti -inflammatory e.g., fluticasone propionate
  • Beclomethasone - In certain aspects the steroidal anti-inflammatory can be beclomethasone dipropionate or its monohydrate.
  • Beclomethasone dipropionate has the chemical name 9-chloro-l lb, 17,21-trihydroxy-16b-methylpregna-l,4-diene-3,20- doine 17,21 -dipropionate.
  • the compound may be a white powder with a molecular weight of 521.25; and is very slightly soluble in water (Physicians' Desk Reference), very soluble in chloroform, and freely soluble in acetone and in alcohol.
  • Providing steroidal anti -inflammatories may enhance the compositions and methods by, for example, attenuating any unwanted inflammation.
  • examples of other steroidal anti-inflammatories for use herein include, but are not limited to, betamethasone, triamcinolone, dexamethasone, prednisone, mometasone, flunisolide and budesonide.
  • the non-steroidal antiinflammatory agent may include aspirin, sodium salicylate, acetaminophen, phenacetin, ibuprofen, ketoprofen, indomethacin, flurbiprofen, diclofenac, naproxen, piroxicam, tebufelone, etodolac, nabumetone, tenidap, alcofenac, antipyrine, amimopyrine, dipyrone, animopyrone, phenylbutazone, clofezone, oxyphenbutazone, prexazone, apazone, benzydamine, bucolome, cinchopen, clonixin, ditrazol, epirizole, fenoprofen, floctafeninl, flufenamic acid, glaphenine, indoprofen, meclofenamic acid, mefenamic acid, n
  • Suitable pharmaceutically acceptable excipients may be volatile or nonvolatile. Volatile excipients, when heated, are concurrently volatilized, aerosolized and inhaled. Classes of such excipients are known in the art and include, without limitation, gaseous, supercritical fluid, liquid and solid solvents. The following is a list of exemplary carriers within these classes: water; terpenes, such as menthol; alcohols, such as ethanol, propylene glycol, glycerol and other similar alcohols; dimethylformamide; dimethylacetamide; wax; supercritical carbon dioxide; dry ice; and mixtures thereof. In certain aspects glycerol is utilized as an excipient.
  • compositions described herein may be comprised in a kit.
  • reagents for production and/or delivery of a TLR or O/P composition are included in a kit.
  • the kit is portable and may be carried on a person much like an asthma inhaler is carried.
  • kits may be packaged either in an aqueous, powdered, or lyophilized form.
  • the container means of the kits will generally include at least one inhaler, canister, vial, test tube, flask, bottle, syringe or other container means, into which a component may be placed, and preferably, suitably aliquoted. Where there is more than one component in the kit (second agent, etc.), the kit also will generally contain a second, third or other additional container into which the additional components may be separately placed.
  • a container can include a canister or inhaler that can be worn on a belt or easily carried in a pocket, backpack or other storage container.
  • Kits also may include a container for the described compositions or their variations, and any other reagent containers in close confinement for commercial sale. Such containers may include injection or blow molded plastic containers into which the desired vials are retained.
  • the components of the kit are provided in one and/or more liquid solutions, e.g., the liquid solution is an aqueous solution, with a sterile aqueous solution being particularly preferred, but not required.
  • the components of the kit may be provided as dried powder(s).
  • the powder When reagents and/or components are provided as a dry powder, the powder may be reconstituted by the addition of a suitable solvent or administered in a powdered form. It is envisioned that a solvent may also be provided in another container means.
  • kits will also include instructions for employing the kit components as well the use of any other reagent not included in the kit. Instructions may include variations that can be implemented.
  • kits are embodiments of kits. Such kits, however, are not limited to the particular items identified above and may include any reagent used directly or indirectly in the detection of pathogenic microorganisms or administration of a StIR composition.
  • Aerosolized OVA-O/P reduces total- and OVA-IgE serum levels.
  • Preliminary studies with aerosolized O/P have demonstrated a powerful defensive response of the airway epithelium that can prevent respiratory infections caused by various viruses (Evans et al., Annu Rev Physiol (2010), 72:413-35; Clement et al., Am J Respir Crit Care Med (2008), 177: 1322-30; Evans et al., Am J Respir Cell Mol Biol (2010), 42:40- 50; Tuvim et al., PLoS ONE (2009) 4:e4176).
  • FIG. 1 A To assess possible beneficial or harmful effects of O/P on allergic asthma, the inventors used a conventional mouse (BALB/c) ovalbumin sensitization and challenge model (FIG. 1 A). The inventors assessed atopy, the allergic phenotype, by measuring serum IgE. Examination of total IgE levels in mice immunized and challenged with aerosolized OVA +/- O/P revealed a marked increase between aerosol-challenged mice (FIG. IB, groups 4-8) and those that were immunized only (FIG. IB, groups 2-3).
  • BALB/c ovalbumin sensitization and challenge model
  • Aerosolized OVA-O/P increases serum IgG2a and IgGl levels.
  • the inventors assessed the IgG immunoglobulin subclasses to determine whether the OVA- O/P aerosol challenge model modulated the immune response by measuring total IgG, IgGl, and IgG2a serum levels (FIG. 2). All mice immunized and aerosol challenged with OVA showed increased serum levels of total IgG (FIG. 2, top panel, groups 3-4, 6-8), whereas mice given O/P (PUL-042) alone by aerosol did not (FIG. 2, top panel, group 5). Increased total IgG levels reflects a successful immunization protocol.
  • mice treated with OVA alone did not reveal a significant difference in total IgG between the two groups (FIG. 2, top panel, group 4 vs group 6).
  • mice in Groups 8 and 9 had the highest total leukocyte count as compared to other groups (FIG. 3B). In addition, this same group had the highest total eosinophil (EOS) count as compared to the other groups (FIG. 3B).
  • EOS eosinophil
  • mice Female BALB/c mice (6-10 weeks of age) were purchased from Charles River, Wilmington, MA, and housed five mice per cage in a 12/12h light/dark cycle with food and water available ad libitum. All experimental procedures were approved by the institutional animal ethics committee (IAUCUC) at the Institute of Biosciences and Technology, Texas A&M HSC.
  • O/P Synthetic TLR ligands
  • O/P Synthetic TLR ligands
  • PBS 8 ml sterile PBS at the following concentrations: Pam2 10 ⁇ g/ml; ODN2395 20 ⁇ g/ml.
  • Mice were sensitized to ovalbumin (OVA) (20 g OVA, Grade V, 2.25 mg alum in saline, pH7.4; Sigma, St. Louis, MO) administered by intraperitoneal (IP) injection once weekly for one or two weeks.
  • OVA ovalbumin
  • IP intraperitoneal
  • Sensitized mice were exposed for 30 min to an aerosol of 2.5% (wt/vol) ovalbumin in 0.9% saline, via Aerotech II nebulizer (CIS US, Inc.) combined with or without O/P in the presence of room air supplemented with 5% CO2 to promote maximal ventilation and homogeneous aerosol exposure throughout the lungs.
  • Aerotech II nebulizer CIS US, Inc.
  • Enzyme -linked immunosorbent assay for immunoglobulin measurement Serum immunoglobulin concentrations were determined by standard sandwich ELISA technique using 96 well Easywash high binding flat bottom plates (Corning). All reagents were diluted in assay diluent (TBS + 0.1% BSA [Calbiochem]) except for the coating reagent, which was diluted in TBS only. All wells were washed with wash buffer (TBS + 0.1% Tween-20) 3Xs, 5 minutes per wash, and all samples developed by adding TMB Substrate Reagent (BD Biosciences) for 30 minutes in the dark. Reactions were stopped by addition of 2N H2SO4 and absorbance read at 450 nm. All readings used in the data fell within the linear portion of the standard curves.
  • Fortotal IgGl 2 ⁇ g/mL Rat Anti-Mouse IgGl (BioLegend, clone RMGl-1), 0.05 ⁇ g/mL Biotin Rat Anti- Mouse IgGl (eBioscience, clone M1-14D12).
  • For IgG2a 2 ⁇ g/mL Rat Anti-Mouse IgG2a (BioLegend, clone RMG2a-62) and 0.05 ⁇ g/mL Biotin Goat Anti-Mouse IgG2a (AbD Serotec, 108008).
  • BAL Bronchoalveoloar lavage

Abstract

Certains modes de réalisation concernent des compositions et des méthodes pour atténuer des réponses allergiques chez un sujet.
PCT/IB2017/057025 2016-11-09 2017-11-09 Méthodes et compositions pour une modulation immunitaire adaptative WO2018087699A2 (fr)

Priority Applications (11)

Application Number Priority Date Filing Date Title
AU2017356673A AU2017356673B2 (en) 2016-11-09 2017-11-09 Methods and compositions for adaptive immune modulation
BR112019009469A BR112019009469A2 (pt) 2016-11-09 2017-11-09 métodos e composições para a modulação imunológica adaptativa
CA3043480A CA3043480A1 (fr) 2016-11-09 2017-11-09 Methodes et compositions pour une modulation immunitaire adaptative
KR1020197016471A KR102515202B1 (ko) 2016-11-09 2017-11-09 후천성 면역 조절을 위한 방법 및 조성물
JP2019525874A JP7145853B2 (ja) 2016-11-09 2017-11-09 適応免疫調節のための方法および組成物
CN201780076197.9A CN110234401B (zh) 2016-11-09 2017-11-09 用于适应性免疫调节的方法和组合物
US16/348,829 US11826422B2 (en) 2016-11-09 2017-11-09 Methods and compositions for adaptive immune modulation
MX2019005502A MX2019005502A (es) 2016-11-09 2017-11-09 Metodos y composiciones para inmunomodulacion adaptativa.
EP17870060.5A EP3538218A4 (fr) 2016-11-09 2017-11-09 Méthodes et compositions pour une modulation immunitaire adaptative
IL266562A IL266562A (en) 2016-11-09 2019-05-12 Methods and methods for adaptive immune regulation
US18/484,667 US20240033348A1 (en) 2016-11-09 2023-10-11 Methods and compositions for adaptive immune modulation

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662419739P 2016-11-09 2016-11-09
US62/419,739 2016-11-09

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US16/348,829 A-371-Of-International US11826422B2 (en) 2016-11-09 2017-11-09 Methods and compositions for adaptive immune modulation
US18/484,667 Continuation US20240033348A1 (en) 2016-11-09 2023-10-11 Methods and compositions for adaptive immune modulation

Publications (2)

Publication Number Publication Date
WO2018087699A2 true WO2018087699A2 (fr) 2018-05-17
WO2018087699A3 WO2018087699A3 (fr) 2018-06-28

Family

ID=62109692

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2017/057025 WO2018087699A2 (fr) 2016-11-09 2017-11-09 Méthodes et compositions pour une modulation immunitaire adaptative

Country Status (11)

Country Link
US (2) US11826422B2 (fr)
EP (1) EP3538218A4 (fr)
JP (1) JP7145853B2 (fr)
KR (1) KR102515202B1 (fr)
CN (1) CN110234401B (fr)
AU (1) AU2017356673B2 (fr)
BR (1) BR112019009469A2 (fr)
CA (1) CA3043480A1 (fr)
IL (1) IL266562A (fr)
MX (1) MX2019005502A (fr)
WO (1) WO2018087699A2 (fr)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110714000A (zh) * 2019-10-29 2020-01-21 重庆医科大学 一种Toll样受体配体蛋白在抗细菌感染中的应用
US11364304B2 (en) 2016-08-25 2022-06-21 Northwestern University Crosslinked micellar spherical nucleic acids
US11433131B2 (en) 2017-05-11 2022-09-06 Northwestern University Adoptive cell therapy using spherical nucleic acids (SNAs)
WO2023028649A1 (fr) * 2021-08-31 2023-03-09 Ena Respiratory Pty Ltd Traitement des allergies
EP4087931A4 (fr) * 2020-01-10 2024-01-24 Sbi Biotech Co Ltd Nouveaux agonistes de tlr9

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115836646B (zh) * 2022-11-28 2023-09-26 贵州省林业学校(贵州省林业干部学校) 一种山桐子的组织培养方法

Citations (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4668218A (en) 1985-04-12 1987-05-26 Aktiebolaget Draco Indicating means for a dosage dispensing device
US4689338A (en) 1983-11-18 1987-08-25 Riker Laboratories, Inc. 1H-Imidazo[4,5-c]quinolin-4-amines and antiviral use
EP0237507A1 (fr) 1986-03-07 1987-09-16 Aktiebolaget Draco Dispositif d'inhalation de poudre
US4929624A (en) 1989-03-23 1990-05-29 Minnesota Mining And Manufacturing Company Olefinic 1H-imidazo(4,5-c)quinolin-4-amines
US5238944A (en) 1988-12-15 1993-08-24 Riker Laboratories, Inc. Topical formulations and transdermal delivery systems containing 1-isobutyl-1H-imidazo[4,5-c]quinolin-4-amine
US5266575A (en) 1991-11-06 1993-11-30 Minnesota Mining And Manufacturing Company 2-ethyl 1H-imidazo[4,5-ciquinolin-4-amines
US5268376A (en) 1991-09-04 1993-12-07 Minnesota Mining And Manufacturing Company 1-substituted 1H-imidazo[4,5-c]quinolin-4-amines
WO1994006498A1 (fr) 1992-09-23 1994-03-31 Fisons Plc Inhalateur
WO1994008552A2 (fr) 1992-10-19 1994-04-28 Dura Pharmaceuticals, Inc. Inhalateur pour poudre seche
WO1994016970A1 (fr) 1993-01-19 1994-08-04 Glaxo Group Limited Dispositif
US5352784A (en) 1993-07-15 1994-10-04 Minnesota Mining And Manufacturing Company Fused cycloalkylimidazopyridines
US5389640A (en) 1991-03-01 1995-02-14 Minnesota Mining And Manufacturing Company 1-substituted, 2-substituted 1H-imidazo[4,5-c]quinolin-4-amines
US5395937A (en) 1993-01-29 1995-03-07 Minnesota Mining And Manufacturing Company Process for preparing quinoline amines
US5458135A (en) 1991-07-02 1995-10-17 Inhale Therapeutic Systems Method and device for delivering aerosolized medicaments
US5482936A (en) 1995-01-12 1996-01-09 Minnesota Mining And Manufacturing Company Imidazo[4,5-C]quinoline amines
US5494916A (en) 1993-07-15 1996-02-27 Minnesota Mining And Manufacturing Company Imidazo[4,5-C]pyridin-4-amines
WO1997025086A2 (fr) 1996-01-03 1997-07-17 Glaxo Group Limited Dispositif d'inhalation
WO1998016427A1 (fr) 1996-10-11 1998-04-23 Pactec Verpackungsmaschinen-Fabrik Theegarten Gmbh & Co. Kg Dispositif pour emballer des articles de petite taille dans des enveloppes pliables
WO1998035888A1 (fr) 1997-02-13 1998-08-20 Glaxo Group Limited Valve doseuse pour aerosols
WO1998055495A2 (fr) 1997-06-06 1998-12-10 Dynavax Technologies Corporation Oligonucleotides immunostimulateurs, compositions correspondantes et leurs procedes d'utilisation
US6039969A (en) 1996-10-25 2000-03-21 3M Innovative Properties Company Immune response modifier compounds for treatment of TH2 mediated and related diseases
US6110929A (en) 1998-07-28 2000-08-29 3M Innovative Properties Company Oxazolo, thiazolo and selenazolo [4,5-c]-quinolin-4-amines and analogs thereof
WO2000076518A1 (fr) 1999-06-10 2000-12-21 3M Innovative Properties Company Imidazoquinolines substituees par uree
US6194425B1 (en) 1997-12-11 2001-02-27 3M Innovative Properties Company Imidazonaphthyridines
US6331539B1 (en) 1999-06-10 2001-12-18 3M Innovative Properties Company Sulfonamide and sulfamide substituted imidazoquinolines
WO2002046193A2 (fr) 2000-12-08 2002-06-13 3M Innovative Properties Company Imidazoquinolines substituees ether heterocyclique
US6451810B1 (en) 1999-06-10 2002-09-17 3M Innovative Properties Company Amide substituted imidazoquinolines
US6488953B2 (en) 1998-12-01 2002-12-03 Controlled Therapeutics (Scotland) Ltd. Oral transmucosal delivery
US20030225016A1 (en) 2001-06-21 2003-12-04 Fearon Karen L. Chimeric immunomodulatory compounds and methods of using the same - III
US6737045B2 (en) 1994-03-07 2004-05-18 Nektar Therapeutics Methods and compositions for the pulmonary delivery insulin
US20040162309A1 (en) 2003-02-13 2004-08-19 3M Innovative Properties Company Methods and compositions related to IRM compounds and toll-like receptor 8
US20040171086A1 (en) 2003-02-27 2004-09-02 3M Innovative Properties Company Selective modulation of TLR-mediated biological activity
US6794357B1 (en) 1993-06-24 2004-09-21 Astrazeneca Ab Compositions for inhalation
US6797258B2 (en) 1992-07-08 2004-09-28 Nektar Therapeutics Compositions and methods for the pulmonary delivery of aerosolized macromolecules

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7585847B2 (en) * 2000-02-03 2009-09-08 Coley Pharmaceutical Group, Inc. Immunostimulatory nucleic acids for the treatment of asthma and allergy
EP1979488A4 (fr) * 2006-01-09 2009-05-27 Univ California Combinaisons immunostimulatrices de tnfrsf, tlr, nlr, rhr, du récepteur purinergique et des agonistes du récepteur de la cytokine utilisées pour les vaccins et en immunothérapie anti-tumorale
CA2646539A1 (fr) * 2006-03-23 2007-09-27 Novartis Ag Composes d'imidazoquinoxaline utilises en tant qu'immunomodulateurs
WO2007118901A2 (fr) * 2006-04-18 2007-10-25 The Provost, Fellows And Scholars Of The College Of The Holy And Undivided Trinity Of Queen Elizabeth Near Dublin Procedes et compositions permettant de moduler une reponse immunitaire
PL2032592T3 (pl) * 2006-06-12 2013-11-29 Kuros Biosciences Ag Sposoby pakowania oligonukleotydów do cząstek wirusopodobnych z bakteriofagów RNA
RU2009115687A (ru) * 2006-10-26 2010-11-10 Коли Фармасьютикал Гмбх (De) Олигорибонуклеотиды и их применения
WO2009088401A2 (fr) * 2007-09-24 2009-07-16 Government Of The Usa, As Represented By The Secretary, Dept. Of Health And Human Services Combinaisons immunostimulantes de ligands tlr et leurs procédés d'utilisation
PT2411521E (pt) * 2009-03-25 2015-04-21 Univ Texas Composições para estimulação de resistência imunitária inata de mamíferos contra patogénicos
ES2443952T3 (es) 2009-09-02 2014-02-21 Novartis Ag Composiciones inmunógenas que incluyen moduladores de la actividad de TLR
WO2012049312A1 (fr) 2010-10-15 2012-04-19 Alk-Abelló A/S Suppression d'une réponse immunitaire d'hypersensibilité de type 1 par un antigène non apparenté
CN109806387B (zh) * 2012-07-13 2022-03-04 S-目标疗法有限公司 免疫调节疫苗
US9688992B2 (en) 2012-11-29 2017-06-27 Sbi Biotech Co., Ltd. Inhibitory oligonucleotide and use thereof
EP2950095B1 (fr) 2014-05-28 2018-08-29 Technische Universität Dresden Analyse cellulaire et procédés de criblage de modulateurs de signalisation de p75NTR
WO2016044839A2 (fr) * 2014-09-19 2016-03-24 The Board Of Regents Of The University Of Texas System Compositions et méthodes pour traiter des infections virales par le biais de l'immunité innée stimulée en combinaison avec des composés antiviraux
WO2016161372A1 (fr) * 2015-04-01 2016-10-06 President And Fellows Of Harvard College Immunoconjugués pour la programmation ou reprogrammation de cellules
DE102021126075A1 (de) 2021-10-07 2023-04-13 Bayerische Motoren Werke Aktiengesellschaft Batteriegehäuse mit Druckausgleichsfunktion, Druckausgleichselement, Antriebsbatterie und Kraftfahrzeug

Patent Citations (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4689338A (en) 1983-11-18 1987-08-25 Riker Laboratories, Inc. 1H-Imidazo[4,5-c]quinolin-4-amines and antiviral use
US4668218A (en) 1985-04-12 1987-05-26 Aktiebolaget Draco Indicating means for a dosage dispensing device
EP0237507A1 (fr) 1986-03-07 1987-09-16 Aktiebolaget Draco Dispositif d'inhalation de poudre
US5238944A (en) 1988-12-15 1993-08-24 Riker Laboratories, Inc. Topical formulations and transdermal delivery systems containing 1-isobutyl-1H-imidazo[4,5-c]quinolin-4-amine
US4929624A (en) 1989-03-23 1990-05-29 Minnesota Mining And Manufacturing Company Olefinic 1H-imidazo(4,5-c)quinolin-4-amines
US5389640A (en) 1991-03-01 1995-02-14 Minnesota Mining And Manufacturing Company 1-substituted, 2-substituted 1H-imidazo[4,5-c]quinolin-4-amines
US5458135A (en) 1991-07-02 1995-10-17 Inhale Therapeutic Systems Method and device for delivering aerosolized medicaments
US5346905A (en) 1991-09-04 1994-09-13 Minnesota Mining And Manufacturing Company 1-substituted 1H-imidazo-[4,5-C]quinolin-4-amines
US5268376A (en) 1991-09-04 1993-12-07 Minnesota Mining And Manufacturing Company 1-substituted 1H-imidazo[4,5-c]quinolin-4-amines
US5525612A (en) 1991-09-04 1996-06-11 Minnesota Mining And Manufacturing Company 1-substituted 1H-imidazo-[4,5-c]quinolin-4-amines
US5266575A (en) 1991-11-06 1993-11-30 Minnesota Mining And Manufacturing Company 2-ethyl 1H-imidazo[4,5-ciquinolin-4-amines
US6797258B2 (en) 1992-07-08 2004-09-28 Nektar Therapeutics Compositions and methods for the pulmonary delivery of aerosolized macromolecules
WO1994006498A1 (fr) 1992-09-23 1994-03-31 Fisons Plc Inhalateur
WO1994008552A2 (fr) 1992-10-19 1994-04-28 Dura Pharmaceuticals, Inc. Inhalateur pour poudre seche
WO1994016970A1 (fr) 1993-01-19 1994-08-04 Glaxo Group Limited Dispositif
US5395937A (en) 1993-01-29 1995-03-07 Minnesota Mining And Manufacturing Company Process for preparing quinoline amines
US6794357B1 (en) 1993-06-24 2004-09-21 Astrazeneca Ab Compositions for inhalation
US5352784A (en) 1993-07-15 1994-10-04 Minnesota Mining And Manufacturing Company Fused cycloalkylimidazopyridines
US5494916A (en) 1993-07-15 1996-02-27 Minnesota Mining And Manufacturing Company Imidazo[4,5-C]pyridin-4-amines
US6737045B2 (en) 1994-03-07 2004-05-18 Nektar Therapeutics Methods and compositions for the pulmonary delivery insulin
US5482936A (en) 1995-01-12 1996-01-09 Minnesota Mining And Manufacturing Company Imidazo[4,5-C]quinoline amines
WO1997025086A2 (fr) 1996-01-03 1997-07-17 Glaxo Group Limited Dispositif d'inhalation
WO1998016427A1 (fr) 1996-10-11 1998-04-23 Pactec Verpackungsmaschinen-Fabrik Theegarten Gmbh & Co. Kg Dispositif pour emballer des articles de petite taille dans des enveloppes pliables
US6039969A (en) 1996-10-25 2000-03-21 3M Innovative Properties Company Immune response modifier compounds for treatment of TH2 mediated and related diseases
WO1998035888A1 (fr) 1997-02-13 1998-08-20 Glaxo Group Limited Valve doseuse pour aerosols
WO1998055495A2 (fr) 1997-06-06 1998-12-10 Dynavax Technologies Corporation Oligonucleotides immunostimulateurs, compositions correspondantes et leurs procedes d'utilisation
US6194425B1 (en) 1997-12-11 2001-02-27 3M Innovative Properties Company Imidazonaphthyridines
US6110929A (en) 1998-07-28 2000-08-29 3M Innovative Properties Company Oxazolo, thiazolo and selenazolo [4,5-c]-quinolin-4-amines and analogs thereof
US6488953B2 (en) 1998-12-01 2002-12-03 Controlled Therapeutics (Scotland) Ltd. Oral transmucosal delivery
US6451810B1 (en) 1999-06-10 2002-09-17 3M Innovative Properties Company Amide substituted imidazoquinolines
US6331539B1 (en) 1999-06-10 2001-12-18 3M Innovative Properties Company Sulfonamide and sulfamide substituted imidazoquinolines
WO2000076518A1 (fr) 1999-06-10 2000-12-21 3M Innovative Properties Company Imidazoquinolines substituees par uree
WO2002046189A2 (fr) 2000-12-08 2002-06-13 3M Innovative Properties Company Imidazoquinolines substituees aryl ether
WO2002046192A2 (fr) 2000-12-08 2002-06-13 3M Innovative Properties Company Imidazoquinolines a substitution thioether
WO2002046193A2 (fr) 2000-12-08 2002-06-13 3M Innovative Properties Company Imidazoquinolines substituees ether heterocyclique
US20030225016A1 (en) 2001-06-21 2003-12-04 Fearon Karen L. Chimeric immunomodulatory compounds and methods of using the same - III
US20040162309A1 (en) 2003-02-13 2004-08-19 3M Innovative Properties Company Methods and compositions related to IRM compounds and toll-like receptor 8
US20040171086A1 (en) 2003-02-27 2004-09-02 3M Innovative Properties Company Selective modulation of TLR-mediated biological activity

Non-Patent Citations (17)

* Cited by examiner, † Cited by third party
Title
BARNES, NATURE REVIEWS IMMUNOLOGY, vol. 8, 2008, pages 183 - 92
CLEMENT ET AL., AM J RESPIR CRIT CARE MED, vol. 177, 2008, pages 1322 - 30
CLEMENT ET AL., AM JRESPIR CRIT CARE MED, vol. 177, 2008, pages 1322 - 30
DUGGAN ET AL., J IMMUNOL, vol. 186, no. 10, 2011, pages 5916 - 26
EVANS ET AL., AM J RESPIR CELL MOL BIOL, vol. 42, 2010, pages 40 - 50
EVANS ET AL., AM J RESPIR CELL MOLBIOL, vol. 42, 2010, pages 40 - 50
EVANS ET AL., ANNU REV PHYSIOL, vol. 72, 2010, pages 413 - 35
EVANS ET AL., BR J PHARMACOL, vol. 163, 2011, pages 195 - 206
FANTA, N ENGL J MED, vol. 360, 2009, pages 1002 - 14
FERRANDON ET AL., NAT REV IMMUNOL, vol. 7, 2007, pages 862 - 74
JAMES ET AL., J ALLERGY CLIN IMMUNOL, vol. 127, 2011, pages 509 - 16
KARSTEN ET AL., NAT MED, vol. 18, 2012, pages 1401 - 06
KRUG ET AL.: "Identification of CpG oligonucleotide sequences with high induction of IFNalpha/beta in plasmacytoid dendritic cells.", EUR J IMMUNOL, vol. 31, no. 7, 2001, pages 2154 - 63
MARSHALL ET AL.: "Superior activity of the type C class of ISS in vitro and in vivo across multiple species.", DNA CELL BIOL, vol. 24, no. 2, 2005, pages 63 - 72, XP002398078, DOI: 10.1089/dna.2005.24.63
MIZGERD, N ENGL J MED, vol. 358, 2008, pages 716 - 27
TUVIM ET AL., PLOS ONE, vol. 4, 2009, pages e4176
WEST ET AL., ANNU. REV. CELL DEV.BIOL., vol. 22, 2006, pages 409 - 37

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11364304B2 (en) 2016-08-25 2022-06-21 Northwestern University Crosslinked micellar spherical nucleic acids
US11433131B2 (en) 2017-05-11 2022-09-06 Northwestern University Adoptive cell therapy using spherical nucleic acids (SNAs)
CN110714000A (zh) * 2019-10-29 2020-01-21 重庆医科大学 一种Toll样受体配体蛋白在抗细菌感染中的应用
EP4087931A4 (fr) * 2020-01-10 2024-01-24 Sbi Biotech Co Ltd Nouveaux agonistes de tlr9
WO2023028649A1 (fr) * 2021-08-31 2023-03-09 Ena Respiratory Pty Ltd Traitement des allergies

Also Published As

Publication number Publication date
EP3538218A2 (fr) 2019-09-18
EP3538218A4 (fr) 2020-06-17
CN110234401B (zh) 2024-03-01
KR102515202B1 (ko) 2023-03-29
JP2020500189A (ja) 2020-01-09
BR112019009469A2 (pt) 2019-07-30
US20240033348A1 (en) 2024-02-01
WO2018087699A3 (fr) 2018-06-28
AU2017356673B2 (en) 2023-11-09
AU2017356673A1 (en) 2019-05-30
MX2019005502A (es) 2020-10-01
CN110234401A (zh) 2019-09-13
IL266562A (en) 2019-07-31
US11826422B2 (en) 2023-11-28
JP7145853B2 (ja) 2022-10-03
CA3043480A1 (fr) 2018-05-17
US20190269773A1 (en) 2019-09-05
KR20190104519A (ko) 2019-09-10

Similar Documents

Publication Publication Date Title
US20240033348A1 (en) Methods and compositions for adaptive immune modulation
Gunawardana et al. New approaches to allergen immunotherapy
JP4663113B2 (ja) 抗原刺激顆粒球媒介炎症を予防または軽減するための免疫刺激オリゴヌクレオチドの使用
US9050376B2 (en) Conjugates of synthetic TLR agonists and uses therefor
US20030078223A1 (en) Compositions and methods for modulating an immune response
Joshi et al. Development of a poly (lactic-co-glycolic acid) particle vaccine to protect against house dust mite induced allergy
JP2006522135A (ja) 喘息およびアレルギーの処置のための両性イオン免疫調節剤
US11278608B2 (en) Nicotine nanovaccines and uses thereof
JP2016532712A (ja) 薬物中毒に対するワクチン組成物
WO2002074922A2 (fr) Compositions et procedes permettant de moduler une reponse immunitaire
Evans et al. Compositions for stimulation of mammalian innate immune resistance to pathogens
WO2023028649A1 (fr) Traitement des allergies
CA3219814A1 (fr) Compositions de mpla et procedes d'utilisation
Lin et al. Novel adjuvants in allergen-specific immunotherapy: where do we stand?
Parsons et al. Nanosystems for selective epithelial barrier targeting in chronic airway diseases

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 17870060

Country of ref document: EP

Kind code of ref document: A2

ENP Entry into the national phase

Ref document number: 3043480

Country of ref document: CA

Ref document number: 2019525874

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112019009469

Country of ref document: BR

ENP Entry into the national phase

Ref document number: 2017356673

Country of ref document: AU

Date of ref document: 20171109

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 20197016471

Country of ref document: KR

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 2017870060

Country of ref document: EP

Effective date: 20190611

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 17870060

Country of ref document: EP

Kind code of ref document: A2

ENP Entry into the national phase

Ref document number: 112019009469

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20190509